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1General introduCtion

General introduction
11.1  oVarian pHYsioloGY 
embryology 
During the fifth week of fetal life, formation of the genital ridges starts in the posterior 
abdominal wall, in response to colonization by primordial germ cells, migrating 
from the yolk sac.  By the end of the sixth week, the male and female gonads are 
indifferent. Differentiation of the gonads is triggered by the sex-determining-region 
on the Y-chromosome. The first step in male gonadal development is differentiation of 
Sertoli cells, which produce anti-Müllerian hormone (AMH). Subsequently, between 
the eighth and tenth week, AMH induces regression of the Müllerian ducts. Thereafter, 
mesenchymal cells differentiate into Leydig cells, which produce testosterone. 
Further differentiation of the urogenital system into male derivatives is then ensured 
by testosterone. In absence of the sex-determining-region on the Y-chromosome, 
producing the testis determining factor, the gonad differentiates into a female genital 
system. In addition, production of AMH is lacking and Müllerian ducts, also called the 
paramesonephric ducts, continue to differentiate into fallopian tubes, uterus and upper 
part of the vagina. From the seventh week of fetal life onwards, germ cells differentiate 
into oogonia. Through mitotic cell divisions, the number of oogonia increases steadily 
and during the third month, the first oogonia begin to transform into oocytes. From 
the fifth month onwards, the oogonia enter meiosis. In addition, the oocytes are 
encapsuled by a single layer of pregranulosa cells, forming the primordial follicles (1). 
Meiosis is arrested during the first prophase of the first meiotic division, when the 
homologous chromosomes pair and the primordial follicles enter a dormant state. 
menstrual cycle
Menarche is the onset of the menstrual cycle and thus the start of the reproductive 
lifespan, which begins after full establishment of the hypothalamic-pituitary-gonadal 
axis. Normal reproductive function involves monthly follicle development, ovulation 
and preparation of the endometrium for implantation. Follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH) play a central role in the regulation of ovarian 
function. These hormones are produced by the gonadotrophes of the anterior pituitary 
gland. Secretion of the gonadotrophins is regulated by gonadotrophin-releasing 
hormone (GnRH), a decapeptide secreted by the neurons of one of the basal nuclei 
in the hypothalamus. Both gonadotrophins are required for follicular development 
and steroid hormone production in the ovary. These steroid hormones regulate 
gonadotrophin secretion and GnRH pulsatility by positive and negative feedback 
during the menstrual cycle (2). 
During the luteo-follicular transition of a normal menstrual cycle, a certain 
concentration of FSH is needed to recruit follicles. More specifically, only those antral 
follicles responding to the FSH surge during the luteo-follicular transition continue 
to grow.  One of the factors, exerting a negative feedback on FSH secretion is serum 
inhibin B, a member of the TGF-β family (3). It is produced by granulosa cells of small 
antral follicles and serum levels increase with increasing diameters of follicles during 
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the early follicular phase. Subsequently, high inhibin B levels decrease FSH levels via 
a negative feedback, thereby restricting the window of FSH sensitivity and allowing 
only a limited number of small antral follicles to be recruited for further growth and 
development. Follicles that are not responsive to the FSH surge will degenerate and 
become atretic. This process is also referred to as the FSH threshold concept (4). Each 
month a few of these follicles will surpass the ‘FSH threshold’ in order to develop until 
the antral stage. At the end of the follicular phase, only one of these follicles, due to 
differences in size and biopotency will gain dominance and resume gametogenesis 
by completing the first meiotic division. Eventually this follicle will ovulate and upon 
fertilization this oocyte will complete the second meiotic division (Figure 1.1) (1, 4). 
The number of follicles that will ultimately reach the pre-ovulatory stage will 
be limited by the magnitude and duration of FSH stimulation (5). In the end, only 
400 follicles will fully mature and ovulate during a woman’s reproductive lifespan 
resulting in about 400 menstrual cycles. At any point during the menstrual cycle, 
follicles of different developmental stages are present and can become atretic. Indeed, 
the majority of follicles leaving the primordial follicle pool will eventually undergo 
atresia (1). Hence, a follicle seems to be destined to deteriorate rather than to develop 
until the pre-ovulatory stage and ovulate. Therefore, this process of follicle growth, 
development, and selection appears to be quite wasteful. This suggests the presence 
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Figure 1.1. FSH dependent recruitment of antral follicles in the FSH window. 
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1of some regulatory mechanism at various points in folliculogenesis that distinguishes healthy follicles, destined to ovulate, from the less viable ones, those destined to become 
atretic. FSH is one of these regulating factors, because of its important role in follicle 
selection, i.e. FSH-dependent selection of pre-antral follicles and subsequent selection 
for dominance during the antral stage (5).  Functional FSH receptors are not expressed 
in primordial follicles (1, 6, 7). Indeed, recruitment from the primordial follicle pool 
is thought to be independent from FSH (Figure 1.1). Besides FSH itself, the FSH 
sensitivity of antral follicles seems to be regulated by intra-ovarian growth factors (1, 
4). Apparently, these intra-ovarian factors are also key factors of early folliculogenesis 
(8, 9). The transforming growth factor β (TGF-β) superfamily, which includes activins, 
inhibins, growth and differentiation factors, bone morphogenetic proteins and 
several other members such as AMH, has been suggested to affect different steps of 
folliculogenesis, in a paracrine or autocrine fashion (9, 10) (Figure 1.2). The role of 
AMH in the ovary is discussed in paragraph 3.4. 
ovarian reserve throughout life 
Duration of fertility is determined by the number of primordial follicles, the ovarian 
reserve (11). Around the fifth month, a maximum number of approximately 7 million 
germ cells is reached (12-14). Since at this stage, the first oocytes will enter meiosis, their 
number will not increase any further (1, 12). In addition, the oocytes are encapsuled 
by a single layer of pregranulosa cells, forming the primordial follicles. Those oocytes 
that do not become surrounded by pregranulosa cells are lost through apoptosis (1). 
As a result, an exponential decrease in the number of primordial follicles is observed 
until birth and continues during childhood, so that at menarche approximately 500.000 
Figure 1.2. Initial recruitment and cyclic recruitment during stages of folliculogenesis, with 
AMH expression and AMH function.
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primordial follicles remain (13-15). During reproductive lifespan, the number of 
follicles decreases gradually at a fixed rate, until the age of 35 years. From this point 
onwards, follicle loss is accelerated and finally, the primordial follicle pool is exhausted 
and menopause is reached. 
In natural fertility populations, the mean maternal age at the birth of their last child 
is at 40-41 years. This age can be regarded at the mean age at which female fertility comes 
to an end and sterility starts. At that age, most women have seemingly normal regular 
cycles, with a biphasic basal body temperature, reflecting progesterone production 
during the luteal phase. Surprisingly, although the menopause is traditionally regarded 
as the age at which sterility ensues, it occurs about ten years later, at a mean age of 
51 years with a range from 40 to 60 years (16-18). The age at which women become 
sterile shows the same degree of variation as observed for the age of menopause (19). 
Oligomenorrhoea and cycle shortening, which are distinct clinical signs of ovarian 
ageing, do not seem to be indicative of the onset of decreasing fertility. Since the end of 
fertility may be reached about 10 years prior to menopause, the decline of fertility may 
start as early as mid-twenties (20). So, whereas menopause is a clear clinical feature, 
the onset of accelerated follicle loss, and thus decreased fertility are far less distinct. 
Along with this decrease in the number of oocytes, there is also a noticeable decrease 
in oocyte quality (21-25). The primordial follicles leaving the pool later in life have 
been exposed to more environmental disruptors which might damage DNA integrity 
and functionality. Accordingly, more chromosomal abnormalities, such as trisomy 21 
due to non-disjunction of chromosomes in older oocytes, are observed in embryos 
of women of advanced age as compared with those of younger women (21, 26-28). 
Similarly, advanced maternal age is associated with increased rates of miscarriage, 
congenital malformations and stillbirth (11, 24, 29, 30). Hence, both oocyte quantity 
and oocyte quality decrease with increasing age. 
1.2. oVarian patHopHYsioloGY 
anovulation 
Ovarian dysfunction results in subfertility and endocrine disturbances. A woman is 
proven fertile after a spontaneous pregnancy has been established. In females, this 
requires at least the development of a competent oocyte and ovulation. About 80% of 
normal fertile couples will conceive within one year of unprotected intercourse, while 
the remaining 20% is subfertile. Besides physiological ageing, one of the most common 
disorders in female subfertility is anovulation (25, 31). Oligo-ovulation is defined as 
less than 8 ovulations per year and anovulation is defined as no ovulations at all (32). 
Several disorders may coincide with ovarian dysfunction, resulting in anovulation and 
consequently infertility. Classification of anovulatory infertility should serve multiple 
goals (33). First, a correct diagnosis of disease states related to ovarian dysfunction 
might establish short-term (i.e., adrenal tumours, prolactinomas, or autoimmune 
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1disease) and long-term health risks, such as type 2 diabetes mellitus, cardiovascular disease, and endometrial cancer. Secondly, the classification also provides guidance for 
therapy; it should be established whether ovulation induction may be useful. Finally, 
classification may discriminate between patients with favourable or unfavourable 
chances to respond to different ovulation induction strategies, and may help to 
identify the best and most cost effective strategy in a particular patient (33). The 
current classification for anovulatory infertility, supported by the World Health 
Organization (WHO), is based on the measurement of three distinctive hormones 
i.e., FSH, LH and oestradiol. There are three distinct classes to be distinguished: the 
first class, WHO I, includes patients with low gonadotrophin and low oestradiol levels. 
If these women remain anovulatory and thus stay in a hypo-oestrogenic state, they 
are at risk for osteoporosis and probably bone fractures later in life (34, 35). When 
gonadotrophin and oestradiol levels are normal, patients are classified into the second 
class, designated as WHO II. Depending on the definition used, this class also includes 
a smaller or larger number of women suffering from polycystic ovary syndrome 
(PCOS), the most common endocrinopathy in women of reproductive age. Women 
with PCOS may present with oligo-anovulation, hyperandrogenism and/or polycystic 
ovarian morphology on ultrasound (33, 36). There is clear evidence that women with 
PCOS are at increased risk for developing type 2 diabetes mellitus (37-39). Those 
women suffering from oligomenorrhea or amenorrhea also have a life time increased 
risk to develop endometrial cancer. In addition, PCOS seems to be associated with 
unfavourable lipid profiles and other cardiovascular disease markers. It remains to be 
established whether hard endpoints, such as hypertension,  ischaemic heart disease and 
cerebrovascular accidents are also increased in these women (40-42). Finally, patients 
with hypergonadotrophic, hypo-oestrogenic anovulation constitute the WHO III class. 
In fact this is the end point of every woman’s reproductive life. In some women this 
phase might ensue prematurely, leading to premature ovarian insufficiency (POI). 
Apparently, the ovary is not responsive, despite extremely elevated gonadotrophin 
levels, because the primordial follicle pool has become exhausted. These women may 
have postmenopausal symptoms and besides the risk of osteoporosis, they might also 
develop cardiovascular disease and possibly Alzheimer’s disease (43). 
Accordingly, in WHO I and II classes, ovulation induction, by increasing 
endogenous FSH levels, will be the first treatment of choice. In WHO III patients, 
endogenous gonadotrophins levels are already increased and due to the exhaustion of 
the primordial follicle pool, in vitro fertilization treatment (IVF) with oocyte donation 
remains the only therapeutic option (33).       
iatrogenic ovarian pathology 
Survival rates of childhood and adult cancer have improved dramatically during 
the last few decades (44). Consequently, long-term effects of chemotherapy and/
or radiotherapy are becoming more apparent. One of the adverse long-term effects 
of cancer treatment is gonadotoxicity and consequently impaired fertility (45-47). 
Although some chemotherapeutic approaches do not affect the number of primordial 
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follicles, most cancer treatments seem to reduce the number of primordial follicles 
and subsequently give rise to subfertility or even sterility. Currently, options for 
preservation of fertility, such as cryopreservation of ovarian tissue or oocytes, are 
available.  However, due to considerable differences in numbers of primordial follicles 
between women at any given age, markers measuring the actual primordial follicle pool 
are needed. These markers of residual fertility and reproductive potential are needed, 
in order to guide the clinician in appropriately counseling patients and their parents on 
the possibilities to preserve fertility prior to treatment.   
1.3. marKers of oVarian dYsfunCtion 
fsH 
In women with PCOS, FSH levels are within the normal range. It seems that in women 
with PCOS, follicles are less sensitive to FSH so that selection of a dominant follicle fails 
(48). Indeed, after administration of low doses of exogenous FSH, the FSH threshold 
can be easily surpassed and ovulation usually occurs. FSH levels did not seem to be 
correlated with the extent of PCOS or predictive for chances of successful treatment 
outcome (49-51). 
In the ageing ovary, the number of growing follicles has decreased and consequently, 
increasing amounts of FSH are necessary to ensure follicle growth. In addition, due to 
the decreased number of follicles serum inhibin B levels are low and do not exert any 
negative feedback, resulting in a further increase of serum FSH levels (52). However, 
FSH is an indirect marker of ovarian function, since it is produced in the pituitary 
gland at an increased rate due to the release of the negative feedback of inhibins and 
oestrogens which are not produced anymore by the insufficient ovary. Hence, the 
rise in FSH serum concentrations constitute a rather late sign of ovarian ageing (53). 
In addition, for appropriate interpretation of ovarian reserve, FSH levels should be 
assessed during the early follicular phase. 
inhibins
During the late follicular phase, inhibin B production decreases and inhibin A levels 
increase, which is the predominant inhibin during the peri-ovulatory and early luteal 
phase (54). Inhibin B is produced by granulosa cells of developing early antral follicles 
and constitutes a reflection of the number of recruited antral follicles, cyclicly recruited 
by FSH. Hence, in order to reflect the size of ovarian reserve, assessment of inhibin B 
levels is needed during the early follicular phase when small antral follicles are present 
(2, 22). Although inhibin B is a direct product of the ovary and its serum levels correlate 
well with the number of small antral follicles, it is not a direct product of the primordial 
follicle pool (55, 56). Hence, although it constitutes a better marker for ovarian reserve 
than basal FSH levels, it lacks sufficient power to predict the size of the primordial 
follicle pool accurately (22, 57-63).
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1anti-müllerian hormone Recently, serum AMH levels have been described as novel marker of ovarian reserve. In 
rodents, AMH expression starts immediately after birth in granulosa cells of primary 
follicles and increases until follicles reach the small antral stage. From the antral stage 
onwards, AMH expression decreases and is absent in the pre-ovulatory stage (64). This 
specific expression pattern between initial recruitment and cyclic recruitment indicates 
that AMH may have a role in these two important steps during folliculogenesis (1, 65). 
In AMH null mice, an increased number of growing follicles was observed 
concomitant with a smaller primordial follicle pool at the age of 4 months, as compared 
to wild type mice. It was concluded that AMH inhibits initial recruitment, since 
this process was accelerated in absence of AMH and led to earlier depletion of the 
primordial follicle pool (66) (Figure 1.2). In addition, a larger number of small antral 
follicles was observed in adult AMH null mice, despite lower FSH levels. Furthermore, 
the number of large pre-antral follicles was increased at estrous, whereas in wild type 
mice these follicles are not sensitive to FSH. Nevertheless, AMH null mice did not 
have more pre-ovulatory follicles, suggesting that the final selection for dominance was 
not influenced by AMH. It was suggested that the sensitivity for FSH during monthly 
follicle selection was increased in absence of AMH. Hence, AMH seems to reduce FSH 
sensitivity of individual antral follicles  (67, 68) (Figure 1.2). 
In humans, AMH expression was observed in female fetuses from 36 weeks 
onwards and continued until menopause (69-72). Similar to the pattern in mice, AMH 
is expressed in granulosa cells of primary follicles and was highest in small antral 
follicles, suggesting that  AMH may have a comparable role in human folliculogenesis 
(65, 73, 74) (Figure 1.2). This was indeed supported by genetic studies showing that 
a polymorphism in the gene encoding for the AMH type II receptor (AMHRII) was 
associated with the age of menopause. Although this association was only observed 
in interaction with the number of offspring, this finding confirmed that AMH has a 
role in the recruitment of primordial follicles in the human ovary (75). Furthermore, 
polymorphisms in the genes encoding for AMH and AMHRII were associated with 
oestradiol levels during the follicular phase, suggesting that also in human AMH may 
affect FSH sensitivity (76-78).   
Based on the specific expression pattern solely in small growing follicles, between 
initial recruitment and cyclic recruitment, it was suggested that serum AMH levels 
might indirectly reflect the size of the primordial follicle pool, i.e. the ovarian 
reserve. Indeed, in mice, serum AMH levels decreased with increasing age and were 
correlated with the decreasing number of growing follicles. As expected, a strong 
positive correlation was also observed between serum AMH levels and the number of 
primordial follicles. Importantly, AMH expression in the individual growing follicles 
did not change with increasing age, indicating that decreasing serum AMH levels in 
mice reflect the decrease in size of the primordial follicle pool (79). 
Clinical studies confirmed that concentrations AMH levels correlated well with 
antral follicle count. Accordingly, in women of advanced reproductive age, serum AMH 
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levels were already low, whereas FSH and inhibin B levels were still within normal ranges 
(80). Moreover, serum AMH concentrations were more predictive of ovarian response 
to ovarian stimulation during IVF treatment cycles than the traditional markers of 
ovarian reserve (63, 81).  Finally, recent studies have shown that several years prior to 
menopausal transition, serum AMH levels were low or undetectable and were more 
predictive of the onset of menopause compared to estimates based on chronological 
age (82-84). Therefore, serum AMH concentrations are the earliest marker of ovarian 
ageing and best reflect the reproductive decline.
Since serum AMH levels are a direct marker of the number of small growing follicles, 
AMH concentrations may also be used as marker in ovarian pathophysiology, such as 
PCOS. Although the syndrome includes a variety of clinical features, most women with 
PCOS present with polycystic ovaries, in which the number of pre-antral and small 
antral follicles is increased. As expected, also in women with PCOS, the antral follicle 
count was well correlated with serum AMH levels, reflected by the two- to threefold 
increase of both markers in women with PCOS (51). In addition, serum AMH levels 
were also correlated with other PCOS features such as cycle duration, ovarian volume 
and androgen levels (51, 85). Therefore, it was suggested that AMH may be a marker of 
the severity of PCOS and thus of ovarian dysfunction.
antral follicle count 
The number of primordial follicles decreases with increasing age and consequently, the 
number of antral follicles decreases as well. Indeed, the number of primordial follicles 
is indirectly reflected by the number of growing follicles (86). Therefore, the antral 
follicle count (AFC), defined as all follicles between 2 to 10 mm in diameter, is a good 
marker for ovarian ageing. Indeed, AFC was predictive for the number of oocytes 
retrieved after ovarian stimulation (86, 87). Transvaginal ultrasound provides the most 
direct way to assess the antral follicle count. However, reproducibility of antral follicle 
count seemed to be rather limited, both within and between observers (88, 89). 
One of the phenotypical characteristics of PCOS is an increased number of antral 
follicles (36).  It has been suggested that the failure of follicle selection by FSH results in 
accumulation of follicles. However, recent studies showed that not only early follicular 
growth is enhanced in ovaries of PCOS women but there is also a reduced rate of 
follicle loss as compared to that in normo-ovulatory women (90, 91). Although the 
etiology of PCOS remains unclear, the cohort of primary and secondary follicles is 
increased in PCOS (48). Indeed, the extent of anovulation seems to be correlated with 
a higher number of follicles (92). In addition, an appearance of ovaries on ultrasound 
was a predictive factor for the outcome of ovulation induction treatment with 
gonadotrophins (93). 
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11.4. outline of tHe tHesis 
The aim of this thesis was to study clinical applications of serum AMH measurements. 
First, normal ranges of serum AMH values in healthy subjects from childhood to 
menopause are described in the first chapter. In the second part, the use of AMH as 
marker of ovarian reserve was described in women suspected of impaired fertility. 
These women have been treated with chemotherapy and/or radiotherapy at adult age 
(chapter 3.1) or during childhood (chapter 3.2). In addition, pregnancy outcome was 
described in female cancer survivors (chapter 3.3). In the third part, the role of AMH 
as a marker of ovarian dysfunction is studied. In chapter 4.1 the role of AMH in the 
diagnosis of anovulatory infertility was studied. In addition, the diagnostic value of 
AMH as predictor of ovarian response during ovulation induction treatment in women 
with PCOS was studied (chapter 4.2). Chapter 4.3 focuses on the predictive value of 
AMH for embryo quality. Finally, the last chapter provides a general discussion on the 
application of serum AMH levels in clinical practice and recommendations for future 
research.
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abstraCt 
Background: Anti-Müllerian hormone (AMH) is a novel marker of ovarian reserve. 
However, sufficiently large sets of normative data from infancy to the end of reproductive 
life are still lacking. 
Objective: assessment of serum AMH levels in healthy females in relation with follicle 
stimulating hormone and antral follicle count. 
Subjects: In 804 healthy females ranging from infancy until the end of the reproductive 
period serum AMH levels were measured with an ultrasensitive enzyme-linked 
immunometric assay. All adults had regular menstrual cycles. The majority was proven 
fertile and  none of them had used oral contraceptive pills three months prior to 
assessment. 
Results: In the total cohort, AMH was inversely correlated with age (r = -0.24; P < 
0.001). The age at which the maximum AMH value was attained was at 15.8 years. 
In girls younger than 15.8 years, serum AMH and age were positively correlated (r = 
+0.18; P = 0.007). Thereafter, AMH levels remained stable (r = -0.33; P = 0.66). From 
the age of 25.0 years, there was an inverse correlation between AMH and age (r = -0.47; 
P < 0.001). At any given age, considerable inter-individual differences in serum AMH 
levels were observed.
Conclusions: Follicular dynamics during childhood seem to differ from that at adult 
age. During infancy and puberty, AMH levels increase, whereas during adolescence, 
levels stabilize and adult follicular dynamics are established. Hence, serum AMH 
levels seem to constitute a valuable marker of ovarian reserve only from the age of 25 
years onwards. Our nomogram may facilitate counseling women on their reproductive 
potential.  
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serum amH from birth to adulthood
2
introduCtion 
Serum anti-Müllerian hormone (AMH) is solely produced in the human ovary by 
granulosa cells (73). AMH expression starts in primary follicles as soon as recruitment 
from the primordial follicle pool is initiated, until the early antral stage during which 
expression is strongest (64, 73, 77). Expression ceases in follicles with a diameter 
between 8 × 10 mm (73). Based on this expression pattern, serum AMH was suggested 
to reflect the number of early growing follicles (73). Indeed, in mice serum AMH levels 
correlated strongly with the number of small growing follicles, and more importantly 
with the number of primordial follicles (79). Although direct assessment of the 
primordial follicle pool in women is difficult, one study using oophorectomy for benign 
gynecological reasons confirmed the correlation between serum AMH and primordial 
follicle number in women (94). In addition, several clinical studies have confirmed the 
strong correlation between serum AMH and antral follicle count (AFC) (70, 80, 92), 
and AMH seems the most accurate proxy for not only the cohort of small growing 
follicles, but also for the actual size of the primordial follicle pool (80). Furthermore, it 
was shown that AMH can be used as a marker of diminished ovarian reserve (70, 80, 
95). Similar to AFC, AMH has been shown to be a better predictor of poor response 
to controlled ovarian hyperstimulation than age, serum follicle stimulating hormone 
(FSH) or serum inhibin B concentrations (81, 96, 97). 
Besides being a marker of ovarian reserve, AMH was also described as marker for 
an excess of growing follicles in normogonadotropic normoestrogenic anovulatory 
infertility and polycystic ovary syndrome (PCOS). As compared with women with 
regular menstrual cycles, two to three fold higher AMH levels have been observed in 
women with PCOS (51, 85). Although, serum AMH is used as a marker for ovarian 
function in clinical practice, data on the range of AMH levels in the normal population 
have not been determined and thus, information on cut-off levels of the normal range 
is still lacking. Recently, several studies have aimed to fill this gap in knowledge (97-
102). Although large cohorts were studied, the vast majority of women included in 
these studies were recruited at fertility clinics (97, 98, 100, 101) and may therefore not 
represent normo-ovulatory women. The present study is unique, by measuring serum 
AMH levels in a large cohort of healthy females, ranging from infancy to the end of 
reproductive lifespan, in a single laboratory. In addition, most of the described women 
of reproductive age were proven fertile. 
materials and metHods
subjects 
Healthy children, adolescents and adult women were included. Most subjects had 
participated in earlier studies as healthy control subjects. For detailed information on 
recruitment strategy and study populations, we refer to the original papers (70, 80, 86, 
103-106). All studies had been previously approved by the different local ethical review 
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boards. All subjects had given written informed consent. Healthy girls aged up to 18 
years were recruited at local primary and secondary schools or at the Sophia Children’s 
hospital prior to minor surgery. Adults (18 years and older) had regular menstrual 
cycles between 25 and 35 days (70, 80, 86, 103-105) or were proven fertile (106). Adults 
did not use any hormones or oral contraceptive pills during the last three months prior 
to participation. Proven fertile women at had given birth at least six months earlier 
(106). Serum was drawn randomly during the menstrual cycle. In those adult women 
screened during the early follicular phase, also serum FSH was measured (70, 80, 86, 
103). In adults, transvaginal ultrasound was performed on cycle day 3, 4 or 5 to assess 
AFC (80, 86, 88, 103, 105). 
Hormone assays
All serum measurements were performed within one laboratory at the Erasmus 
MC, Rotterdam, the Netherlands (FdJ). All samples had been stored at – 20˚C until 
assayed. AMH immunoreactivity in serum samples was stable after repeated freeze–
thaw cycles (79). In the older cohorts  (70, 80, 86), AMH was measured with an 
ultrasensitive enzyme-linked immunosorbent assay (ELISA) (Immunotech-Coulter, 
Marseilles, France) (80) and an in-house AMH-ELISA (commercially available as the 
GenII Beckman Coulter, Beckman Coulter, Inc., Webster, Texas) was used in study 
subjects, in whom serum was drawn more recently (76). The values obtained with the 
Immunotech assay were adjusted with a factor 1.564 for comparison with the currently 
used ELISA. Intra-assay and interassay coefficients of variation in the Immunotech-
Coulter assay were <5% and 8%, and <5% and <10% in the in-house ELISA. The 
detection limit of the currently used ELISA, defined as the mean of the absorbance of 
the blank replicates + 2 SDs, was 6.3 pg/ml. For analysis, serum AMH levels below 0.1 
microg/L were valued at 0.0 microg/L. FSH was measured with a fluorescence-based 
immunoassay (Immulite, Diagnostic Products Corp., Los Angeles, CA, USA), with 
intra- and interassay coefficients of variance <3% and 8%. 
data analysis 
Because samples were obtained from subjects that had participated in different studies, 
AMH levels were compared between the included study cohorts with a univariate 
analysis of covariance with adjustment for age. Since serum was drawn across the 
follicular and luteal phase of the menstrual cycle, a similar test was used to compare 
AMH levels drawn during the follicular phase with those drawn during the luteal phase. 
Reference curves for serum AMH levels as function of age were calculated from a 
linear regression model using a natural cubic spline fitted on log-transformed AMH 
values. From the fitted curve, a piecewise linear function was calculated to describe 
variation in AMH levels with increasing age. In addition, we determined the age at 
which AMH values attained their maximum value, and the 95% CI interval of this age 
was determined by bootstrapping 5000 times. Consequently, two  subgroups could be 
distinguished: one with increasing AMH levels and a subgroup with decreasing AMH 
levels. In the total cohort as well as in subgroups, bivariate correlations were performed 
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between serum AMH and age. In addition, a bivariate correlation was performed 
between serum AMH levels and the number of follicles. This correlation was also 
performed between serum AMH levels and FSH levels in samples drawn during the 
early follicular phase. 
results 
A total of 804 healthy infants, children, adolescents and adult women were included. 
The median age was 24.6 years. The youngest subject was 3.1 months old and the 
oldest was 46.8 years old. Measurement of AMH concentrations using the two AMH 
ELISAs did not result in significant differences (median 1.6 vs. 3.3 µg/L;  P = 0.11) (80). 
There were no differences in AMH levels drawn during the follicular phase and those 
measured during the luteal phase after adjustment for age differences (median 1.9 vs. 
3.3 µg/L, respectively; P = 0.08).  
In the total cohort, serum AMH levels were inversely correlated with age (r = 
-0.24; P < 0.001). The natural cubic spline function explained 41% of the variance in 
log(AMH), indicating that variance in AMH was for 41% determined by age. The fitted 
curve showed that, from birth onwards, serum AMH levels increased slightly until 
the end of puberty and seemed to remain rather constant until levels decreased from 
the age of 25.0 onwards (Figures 2.1 and 2. 2). The piecewise linear function failed to 
show a significant rise in AMH levels during childhood or an attenuation in AMH 
during adolescence (data not shown). The age at which the maximum value of AMH 
was attained was estimated as 15.8 years (95% CI 13.5 to 20.3). Prior to the age of 15.8 
years, serum AMH and age were positively correlated (r = +0.18; P = 0.007). Thereafter, 
AMH levels remained stable, and consequently, the correlation between AMH and age 
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Figure 2.1. Anti-Müllerian hormone (AMH) nomogram based on natural linear spline 
interpolation. Reference lines of serum AMH for the 10th, 50th and 90th percentile of predicted 
AMH values versus age.
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Figure 2.2. Serum anti-Müllerian 
hormone (microg/L) levels per subgroup 
based on age. Reference lines of serum 
AMH for the 10th, 50th and 90th percentile 
of predicted AMH values versus age in 
subgroup 0 – 15.8 years (left panel), 16 – 
25 years (right panel) and in women older 
than 25 years (bottom panel).
did not reach statistical significance (r = -0.33; P = 0.66). From the age of 25.0 years, 
there was an inverse correlation between AMH and age (r = -0.47; P < 0.001). 
Antral follicle counts were not available in girls younger than 18 years. In 465 
women, aged 18 years and older, antral follicle counts were available. The median 
antral follicle count was 13 (range 0 - 48). Serum AMH and antral follicle count were 
positively correlated (r = +0.67; P < 0.001). In 253 adults serum was drawn during the 
early follicular phase and the median FSH was 6.4 IU/L (range 2.0 – 35.9 IU/L) . Serum 
AMH and FSH levels were negatively correlated (r = - 0.29; P < 0.001). 
disCussion
In this study, serum AMH levels were assessed in healthy females from birth to the end 
of reproductive life. Our data clearly indicate that the correlation between serum AMH 
levels and age throughout childhood is different from that during the reproductive 
lifespan. Serum AMH levels slightly increased during childhood until the mid-teens, 
and reached a maximum at the age of 15.8 years. Thereafter, AMH levels remained 
stable until early twenties, and from the age of 25 years decreased with increasing age. 
Recently, a study in healthy children has described increasing AMH levels during early 
childhood and thereafter stable AMH concentrations until early adulthood (99). These 
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findings were confirmed in a nomogram based on previously described AMH levels in 
children and adults (102). In addition, the authors conclude that the variation in AMH 
concentrations was mainly determined by factors other than age (102). Indeed, in our 
data the variance AMH levels was for 41% determined by age, and hence, variation 
in AMH concentrations may also be determined by variation in the number of AMH 
producing follicles or by genetic predisposition.
The positive correlation between AMH and age in girls up to 15.8 years is in 
contrast with the negative correlation between AMH levels and age in women older 
of 25 years. Therefore, our data suggest that follicular dynamics during childhood 
differ from that at adult age. Until now, scant data are available on follicular dynamics 
during childhood. Data on follicle counts were unfortunately not available in our 
cohort of girls younger than 18 years. The rising AMH levels during childhood suggest 
that the number of AMH producing granulosa cells increases or that the number of 
small growing follicles, in which AMH expression is strongest, increases (73). It may 
be postulated that prior to menarche, an increasing number of follicles is recruited 
into the growing follicle cohort. Since gonadotropins are absent, these follicles do not 
reach the antral stage and will eventually atrophy. At the age of 15.8 years a peak level 
in serum AMH values is reached, suggesting that until the first years after menarche, 
the size of the growing follicle cohort increases. Possibly, because of irregular FSH 
pulsatility during the first years after menarche (107, 108), cyclic recruitment of small 
antral follicles is not yet very efficient, resulting in irregular ovulations. In addition, 
adrenarche induces an increase in androgen levels prior to the onset of puberty. This 
rise in androgen concentrations may induce atresia of AMH producing follicles (109), 
and consequently, attenuating the increasing size of the AMH producing cohort. In 
the end, these changes during childhood and puberty may inhibit a further increase of 
AMH levels and thereafter, a steady state in AMH levels between the age of 15.8 and 
25.0 years is established. Apparently, cyclic recruitment into the antral stage is more 
organized, as reflected by regular menstrual cycles. 
In contrast to childhood and adolescence, a strong inverse correlation between 
AMH and age was observed from the age of 25 years onwards, confirming results of 
previous studies (100, 110). In one study, the authors showed that a quadratic equation 
was the best model to describe declining serum AMH values with increasing age (100). 
In our data, a quadratic model could not fit the results of our total cohort. However, 
when the quadratic equation was applied to AMH levels in women of 25 years and 
older, a similar curve was obtained as with the natural linear spline interpolation 
model (data not shown). Our data support the earlier described inverse correlation 
between serum AMH levels and the decreasing number of antral follicles in women 
and in rodents (79, 80) and thus, confirm the role of AMH as a proxy of ovarian reserve 
(70, 80). However, our results also suggest that AMH is only applicable as marker of 
ovarian reserve in women of 25 years and older.
As described in the previously mentioned studies (99, 102), we observed a large 
inter-individual variation in AMH levels. Most likely, this variation in AMH levels 
25
may reflect the range in reproductive aging and age of menopause, i.e. from 40 to 60 
years (16). Indeed, it has been shown that the age of menopause was more accurately 
predicted by serum AMH concentrations than by chronological age (83). A recent 
longitudinal cohort study showed that serum AMH levels drawn approximately 10 
years earlier, were highly predictive of the age of menopausal transition (109). The 
authors of this latter study suggested that AMH is capable of predicting future age 
at menopause for a given woman. Hence, it may be proposed that at any age, women 
with AMH at the upper limit of the normal range will enter menopause at a later age as 
compared to women with AMH levels at the lower limit of the normal range. However, 
the mean age of women included in the latter cohort study was 35 years (109), at which 
the inter-individual variation in AMH is smaller than at younger ages, as shown in our 
data. Consequently, a prediction of age of menopause based on AMH levels measured 
at young age has to be interpreted with caution, since such a prediction may be less 
accurate. Furthermore, it remains unknown whether follicle loss follows a similar rate 
in all women and whether the initial number of primordial follicles, endowed during 
early fetal life, is similar in all women. Therefore, additional studies with long term 
follow-up of frequently measured AMH levels in young women are needed to confirm 
whether AMH can predict age of menopausal transition. 
Recent studies in regularly cycling women have remained inconclusive on the 
relation between serum AMH and FSH levels (80, 111-113). In our results, serum 
AMH and FSH levels in women older than 25 years were negatively correlated, despite 
a large inter-individual variation of both hormones. In addition, the inverse correlation 
between AMH and age was stronger than that between FSH and age, suggesting that 
AMH is a more accurate marker of ovarian ageing than FSH (80). 
In conclusion, our results confirm and expand earlier findings of AMH levels across 
the reproductive lifespan. We demonstrated increasing AMH levels during childhood 
until a maximum is reached at the age of 15.8 years. Thereafter, a plateau until the age 
of 25 years was observed. From the age of 25 years onwards, serum AMH correlate 
inversely with age, implying that AMH is only applicable as marker of ovarian reserve in 
women of 25 years and older. Our data further suggest that follicular dynamics during 
childhood are different than at adult age. Our nomogram may facilitate counseling of 
women on their reproductive potential.
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abstraCt
Background: In female cancer survivors, the accelerated loss of primordial follicles as a 
result of gonadal damage may lead to premature ovarian insufficiency (POI). However, 
the extent of the damage is unpredictable. Anti-Müllerian hormone (AMH) constitutes 
a sensitive marker of ovarian reserve. Serum AMH levels were measured to assess sub-
clinical ovarian damage in patients treated with gonadotoxic therapy. 
Methods: In 25 patients with haematological malignancies serum AMH concentrations 
were measured prior to and after cancer therapy and were compared with normo-
ovulatory controls. 
Results: In all patients, AMH concentrations were lower than controls prior to 
treatment. Thirteen patients were treated with multi-drug chemotherapy. Although 
in most patients treated with chemotherapy menstrual cyclicity was restored, median 
serum AMH levels were lower than in controls. Twelve patients had stem cell 
transplantation (SCT) after total body irradiation. They all developed POI and their 
serum AMH concentrations were undetectable. 
Conclusion: Female cancer survivors treated with SCT all developed POI. Hence, 
in these patients fertility preservation should be considered. In patients treated with 
chemotherapy, ovarian reserve seems to be compromised as well. 
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introduCtion 
The number of patients surviving cancer is increasing, hence long-term effects of 
chemotherapy and/or radiotherapy are becoming more apparent (44, 114). The extent 
of gonadal damage depends on the treatment modality, the dose received and patients' 
age. Alkylating agents, such as cyclophosphamide (CY) and procarbazine, as well as 
radiotherapy are highly gonadotoxic. However, non-gonadotoxic drugs in multi-drug 
regimens may have a cumulative toxic effect on reproductive function (115). So far, 
long-term follow-up studies have assessed ovarian function after cancer treatment using 
parameters such as follicle stimulating hormone (FSH) serum levels or clinical end-
points such as cycle length or pregnancy rates (116-122). However, a recent report on 
gonadal function in childhood cancer survivors showed that, notwithstanding regular 
menstrual cycles, in patients treated with chemotherapy and cranial radiotherapy, 
ovarian reserve was compromised as assessed by serum anti-Müllerian hormone 
(AMH) concentrations (116). Moreover, other studies showed that female cancer 
survivors with regular menses and normal serum FSH levels had significantly smaller 
ovaries along with a lower antral follicle count as compared to age-matched controls 
(123, 124). These observations indicate that parameters such as cycle length and FSH 
serum levels are not accurate markers of ovarian function. Serum AMH levels, antral 
follicle count and ovarian volume, appear to be more reliable predictors (116, 123).
Recently, it was shown that serum AMH levels may constitute a valuable marker 
of ovarian reserve (125). Clinical trials indicated that serum AMH concentrations 
correlated well with antral follicle count and age. With increasing age, the number 
of primordial, preantral and small antral follicles declines and concomitantly serum 
AMH levels decrease. Moreover, in ageing females, AMH levels were decreased, while 
other factors associated with perimenopausal status, such as early follicular phase FSH, 
inhibin B or oestradiol serum levels did not change significantly (68, 80, 96). Finally, 
AMH levels are unaffected by cyclic variations or the use of oral contraceptive pills 
(OCP) (126-129). Currently, serum AMH levels seem to represent the most reliable 
marker to determine ovarian reserve.
In the current study, serum AMH concentrations were measured in order to 
assess the ovarian reserve in women previously treated with gonadotoxic agents for 
haematological malignancies. 
materials and metHods 
subjects
Approval for the study was obtained from the local medical ethics review board. 
Written informed consent was obtained from each participant. 
Premenopausal women from whom serum samples were taken before and after 
treatment for haematological malignancy at the Erasmus MC University Hospital 
between January 1995 and December 2004 were eligible.  
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Women without a history of cancer and with a regular menstrual cycle were 
recruited as controls. Inclusion criteria were age between 20 and 35 years, body mass 
index (BMI) between 19 and 26 kg/m2 and normal menstrual cycle length between 26 
and 31 days. These women had participated in previous studies (80, 130). In addition, 
they were healthy and all proven fertile. They did not have any actual or previous 
endocrine disease, they used neither medication, nor oral contraceptive pills (OCPs), 
nor any hormonal treatment. 
study design 
Prior to treatment as well as during follow-up, blood samples were drawn and serum 
was stored at    -20°C. Clinical screening at follow-up included recording of obstetric 
and cycle history, medication use and OCP use (50). Ultrasound scanning included 
measurement of ovarian volume and total number of follicles and was performed by 
a single investigator (SLF). In patients with regular menstrual cycles, screening was 
performed in the early follicular phase (between cycle day 2 and 5). In  patients using 
OCPs, screening was planned at the last day of the pill-free interval (131). Endocrine 
screening included assays of serum gonadotrophins, oestradiol, inhibin B and AMH. 
Luteinizing hormone (LH) and FSH levels were measured using a luminescence based 
immunoassay (Immulite, Diagnostic Products Corp., Los Angeles, CA, USA). A 
radioimmunoassay  was used to assess oestradiol serum levels (Diagnostic Products 
Corp., Los Angeles, CA, USA). Intra- and interassay coefficients of variation were 
less than 5 % and 15 % for LH, less than 3% and 8% for FSH and less than 5% and 
7% for oestradiol. Serum Inhibin B levels were determined using an enzyme-linked 
immunoassay as described earlier (Oxford Bio Innovation, Oxford, United Kingdom) 
(132). Intra- and interassay coefficients of variation were less than 9% and 15%. Serum 
AMH levels were measured by double-antibody enzyme-linked immunosorbent assay 
(ELISA) in serum samples taken before and after treatment as described before (133). 
Intra- and interassay coefficients of variation were 3.6% and 4.0%, respectively. AMH 
immunoreactivity in serum samples was stable for several days at room temperature 
and after repeated freeze-thaw cycles (79). Values were adjusted to allow comparison 
with AMH levels in controls, which were assayed with an ELISA (Immunotech-Coulter, 
Marseille, France) (80). 
statistics
To assess selection bias, general patient characteristics were compared between enrolled 
patients and drop-outs, using non-parametric tests. Similarly, non-parametric tests were 
performed to compare demographic, endocrine, cycle and treatment characteristics 
in patient subgroups. Serum AMH levels were compared using univariate analysis of 
covariance, adjusting for age differences. The decline in AMH levels in controls was 
calculated according to standard formulas for prediction intervals in linear regression 
analysis, reflecting 5th, 50th and 95th percentiles. The formula: AMH*exp(3.47-
0.102*age) reflects the mean decline in AMH levels in controls, adjusting for increasing 
age. The formula: AMH*exp(3.47-0.102*age) ± 1.48*√ (1.013 + ((age-30.48)/38.45)2)) 
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reflects the 5th and 95th prediction intervals for decline of AMH levels, with adjustment 
for increasing age (80). The interval between the first and last visit was calculated using 
the formula: (date of first visit – date of last visit)/365 days. The remaining fraction of 
ovarian function after cancer therapy was calculated according to a formula comparing 
the remaining AMH in serum to the AMH serum level at the first visit, controlling for 
the interval between first and last visit: (AMH at last visit/AMH at first visit)*exp(1/
interval). Statistical analysis was performed using Statistical Package for Social Sciences 
12.0 (SPSS Inc, Chicago, IL). A P value < 0.05 indicates statistical significance. 
results
For 37 patients pretreatment serum samples were available. All patients were treated 
with chemotherapy and/or radiotherapy according to HOVON (Dutch haemato-
oncology association) protocols (http://www.hovon.nl). Diagnosis, treatment protocol 
and cumulative doses of chemotherapy and irradiation were recorded for each patient 
(Table 3.1.1). From 12 women serum was not obtained post-treatment. Two of these 
twelve had died from their disease. Participation was refused in 4 patients with severe 
complaints attributable to their treatment. The remaining 6 patients refused for 
unknown reasons. Amongst the group of drop-outs, a significantly higher number of 
OCP users was observed. In those enrolled, an increased incidence of oligomenorrhea 
before treatment was observed (P < 0.001). Finally, 25 women were eligible for analysis. 
Lost in follow up
n = 12
Participants
n= 25
Age at diagnosis (years) (median; range) 31.5 (20.1 – 35.0) 27.5 (16.0 – 36.7)
Age at follow-up (years) (median; range) 34.4 (24.3 – 41.9) 31.4 (22.2 – 40.6)
BMI at diagnosis (kg/m2) (median; range) 22.7 (18.3 – 33.3) 23.7 (16.9 – 33.1)
Cycle at diagnosis
regular 
oligomenorrhoea
OCP
unknown
2 (16.7%)
0
4 (33.3%)
6 (50.0%)
18 (72.0%)a
5  (20.0%)a
0a
2 (8.0%)
Treatment
Non AA
AA
SCT
1 (8.3%)
5 (41.7%)
6 (50.0%)
 3 (12.0%)
10 (40.0%) 
12 (48.0%)
Table 3.1.1.  Patient characteristics in groups of patients lost in follow-up and participating 
patients.
a = P < 0,001 lost in follow-up group versus participants by Chi-square test; BMI = body mass 
index; OCP = oral contraceptive pills; Non AA= non alkylating chemotherapeutics; AA = 
alkylating agents; SCT = stem cell transplantation. 
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These patients were divided into subgroups according to their treatment, i.e. multi-
drug chemotherapy (group A, n=13) or stem cell transplantation (SCT) after total body 
irradiation (TBI) and high dose cyclophosphamide (CY) (group B, n=12). Group C 
consisted of 42 control women. Patient numbers within group A were too small to 
allow separate analysis between patients treated with ‘non-alkylating agents’ and those 
treated with ‘alkylating agents’. 
treatment 
In group A, 10 patients received alkylating agents, i.e. cyclophosphamide, procarbazine 
and/or ifosfamide. The remaining three were treated with non-alkylating chemotherapy, 
such as methotrexate or idarubicine. In group B, all 12 patients received autologous 
A
N = 13
B
N = 12
C
N= 42
Age at first visit or at treatment (years) 29.4 (16.0 – 36.2) 25.3 (17.9 – 36.6)b* 29.9 (19.6 – 35.6)
Cycle before
regular
irregular
amenorrhoea
OCP
unknown
10 (77%)
3 (23%)
0
0
8 (67%)
2 (17%)
0
0
2 (17%)
42 (100%) c***
AMH before (µg/L) 1.0 (0.01 – 2.9)a** 0.9 (0.12 – 2.2)b* 2.1 (0.1 – 7.4)
Interval (years) 3.4 (1.2 – 10.6)a* 2.8 (1.5 – 11.1)b* 1.6 (1 – 7.3)
Age at last visit  (years) 33.1 (25.7 – 40.6) 28.9 (22.2 – 40.6) 32.9 (21.3 – 37.9)
Cycle after
regular
irregular
amenorrhoea
OCP
unknown
3 (23%)
5 (38%)
2 (15%)
3 (23%)
0
0
11 (92%)
1 (8%)
42 (100%)c**
AMH after (µg/L)
FSH after (IU/L)
Inhibin B after (ng/L)
Oestradiol (pmol/L)
0.3 (0 – 1.9)a*
8.5 (3.8 – 154)a*
35 (9 – 127)a*
239 (27 – 516)
0 (0 – 0)b***
64.4 (7.3 – 313)b***
n.d. (n.d.)b***
37 (10 – 83)b***
1.3 (0 – 5)
5.8 (2.4 – 13.4)
113 (4 – 206)
163 (70 – 620)
Total number of follicles 8 (1 – 15)a** 1 (0 – 3)b*** 14 (2 – 24) 
Median remaining fraction of AMH 73% 13%b*** 84%
Table 3.1.2. Hormonal and sonographic characteristics before and after treatment in group A, B 
and C; patients treated with multi drug-chemotherapy, patients treated with stem cell transplant 
and controls, respectively. 
*= P < 0,05; ** = P  < 0,01; *** = P < 0,001; a= comparison between A and C by Mann-Whitney-U 
test; b = comparison between B and C by Mann-Whitney-U test; c= comparison between A and C, 
B and C by Chi-square test; n.d. = non-detectable; OCP = oral contraceptive pills. 
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or allogenic SCT after a standardized conditioning regimen including TBI (2 Gray 
[Gy] or 2x6 Gy) combined with high dose alkylating chemotherapy (CY 60 mg/kg). 
Serum AMH concentrations were lower in patients as compared to controls (group A 
versus group C: P = 0.007, group B versus group C: P = 0.02) (Table 3.1.2). Moreover, 
patients in group B were younger than controls (P < 0.05) and 20% of the patients was 
oligomenorrhoeic before treatment was started. 
after treatment
At follow-up, 24 patients were in complete remission. Three of them had relapsed, 
but were re-treated successfully. Only one patient was in partial remission. The median 
interval between the pre- and post-treatment visit was 5.0 years (range 1.2 –11.1 years) 
(Table 3.1.2).  
In subgroup A, serum AMH, inhibin B levels and antral follicle count were 
significantly lower than in controls (P = 0.01; P = 0.02; P = 0.006, respectively). In 
addition, FSH levels were significantly increased (P = 0.03). Three (23%) women had 
continued OCPs immediately after finishing chemotherapy. In the group of patients 
with regular menstrual cycles at the start of therapy (n = 10), four (31%) had become 
oligomenorrhoeic and two (15%) amenorrhoeic. Three patients (23%) had regular 
cycles after treatment, of which one was oligomenorrhoeic prior to chemotherapy. The 
cycle pattern did not change in one patient (8%) who suffered from oligomenorrhea 
prior to therapy (Table 3.1.2). 
In group B, serum AMH concentrations were significantly decreased, as were 
inhibin B levels, oestradiol levels and follicle count as compared to group C (P <0.001), 
and FSH serum levels were increased (P <0.001). In addition, all patients in group B 
were amenorrhoeic (Table 3.1.2). 
Prior to therapy, patients were younger than controls and had lower AMH levels 
than controls. Moreover, intervals between the first and last visit were different in 
the three subgroups. Therefore, the remaining fraction in AMH was calculated. In 
subgroup C, the remaining fraction of AMH reflected the normal decline in AMH 
serum levels during one year, independent from baseline AMH levels. Within one 
year, AMH serum levels decreased by 15% (median remaining fraction 85%; range 
0 – 120%) in healthy normo-ovulatory women. The remaining fraction in subgroup A 
(median 73%; range 20% – 110%) was not different from that in controls (P = 0.42). 
In subgroup B, the remaining fraction (median 13%; range 0 – 50%) was significantly 
smaller than in controls (P <0.001) (Table 3.1.2) (Figure 3.1.1). 
In group A, 3 patients conceived spontaneously within 5 years after finishing 
chemotherapy. 
disCussion
Regardless of their age or ovarian function prior to treatment, all patients treated with 
SCT developed premature ovarian insufficiency and their serum AMH concentrations 
35
were undetectable. In accordance to data from literature, the conditioning regimen 
for SCT is a high risk factor for developing ovarian insufficiency (114). Moreover, TBI 
causes irreversible damage to the ovaries (134). Hence, all women treated with SCT, 
especially those receiving TBI, are candidates for fertility preservation techniques, 
such as ovarian cryopreservation or vitrification of oocytes. 
Serum AMH levels as well as antral follicle counts were significantly decreased 
in patients treated with chemotherapy alone. Although most of these patients had 
menstrual cycles  and some of them conceived spontaneously after chemotherapy, 
sub-clinical ovarian damage had occurred. Hence, they might be at risk for premature 
ovarian insufficiency as well and long-term follow up of the reproductive function in 
these patients is necessary. 
Three recent studies have described predictors for ovarian reserve in breast cancer 
survivors. In premenopausal patients treated with gonadotoxic chemotherapy, serum 
AMH and inhibin B levels were decreased after treatment, although the difference was 
statistically not significant. Antral follicle count was identified as the best predictor 
for ovarian function after chemotherapy (135). It may be hypothesized that directly 
after chemotherapy, the number of small growing follicles and eventually the number 
of antral follicles is decreased. Indeed, immediately after chemotherapy AMH levels 
fall rapidly, suggesting that most of the small growing follicles are lost during the first 
3 months after therapy (136). In most of their patients, AMH levels were undetectable 
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Figure 3.1.1. Decrease in serum anti-Müllerian hormone (AMH) levels in relation to age in 
patients treated with multi-drug chemotherapy (black squares and lines) and patients treated 
with stem cell transplant (grey dots and lines) as compared with the decrease in AMH levels 
in healthy controls (dashed lines; upper line = 95th percentile, middle line = 50th percentile and 
lower line = 5th percentile).
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and recovery of ovarian function did not occur, most likely because their ovarian 
reserve prior to therapy was reduced due to advanced age at start of chemotherapy. 
Hypothetically, in younger patients ovarian reserve is also diminished, but menstrual 
cycles will be restored, as observed in the current study. Until now, data are insufficient 
to determine the time-interval needed for recovery (114). In another study, a seemingly 
intact ovarian function was observed in women treated for breast cancer. These patients 
had regular menstrual cycles and normal antral follicle counts. However, most of these 
women had decreased inhibin B levels and 50% of them had increased FSH levels as 
well. Moreover, all these women had had an entire ovary removed for cryopreservation 
prior to treatment. Hence, these women had an additional risk factor for compromised 
ovarian function after cancer therapy (137). 
Prior to therapy, AMH levels in patients were lower than in controls, even 
though the latter group was older. This indicates that ovarian reserve in patients 
was already compromised before any therapy was initiated. Remarkably, all patients 
who developed premature ovarian insufficiency after gonadotoxic chemotherapy had 
pretreatment AMH levels lower than 10th percentile of AMH levels in age-matched 
controls. However, not all patients with pretreatment AMH below this threshold point 
developed premature ovarian insufficiency. Hence, in our study sample, AMH levels 
prior to treatment were not predictive for ovarian reserve after treatment. 
The remaining fraction of AMH in patients treated with chemotherapy alone, 
reflecting the decrease in AMH levels per year, was not significantly different from 
controls. This suggests that ovarian damage following gonadotoxic therapy is due to a 
diminished primordial follicle pool rather than to an increased rate of follicle loss, as 
described earlier (136). 
In conclusion, the present data show that patients receiving TBI developed 
premature ovarian insufficiency. Hence, to these women fertility preservation, either 
through unilateral ovariectomy and subsequent cryopreservation or vitrification of 
collected oocytes, should be offered. In patients treated with multi-drug chemotherapy, 
the ovarian reserve is compromised as well. Although to a lesser extent, these patients 
are also at risk for premature menopause. 
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abstraCt
Background: The aim was to assess possible treatment-induced gonadal damage 
in a cohort of adult female childhood cancer survivors (CCS) using anti-Müllerian 
hormone (AMH), the most sensitive marker of ovarian reserve. 
Methods: A cohort of 185 survivors was compared with 42 control subjects. The 
median follow-up time was 18.1 years (range 4.1 – 43.2 years). 
Results: Median AMH concentrations in the analyzed cohort were not different from 
controls (median 1.7 vs. 2.1 μg/L; P = 0.57). However, AMH levels were lower than 
the 10th percentile of normal values in 27% (49/182) of the survivors. In addition, 
43% (79/182) had AMH levels lower than 1.4 μg/L, a previously established cut-off 
value which predicts ongoing pregnancy after assisted reproduction. There were no 
differences in AMH levels in subgroups classified according to disease. However, 
survivors treated with three or more procarbazine containing chemotherapy cycles 
had significantly lower AMH levels than controls (median 0.5 μg/L; P = 0.004).  Also 
survivors treated with abdominal or total body irradiation had significantly lower 
AMH levels than controls (median <0.1 μg/L; P <0.001). 
Conclusions: AMH can be used to identify subgroups of CCS at risk for decreased 
fertility or premature ovarian failure. In these survivors options for fertility preservation 
should be considered prior to starting treatment since they may be at risk for poor 
chances of pregnancy after assisted reproductive treatment. 
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introduCtion 
Gonadotoxicity is a well-known side effect of cancer therapy in adult survivors. 
Alkylating agents, such as cyclophosphamide and procarbazine, are known to be highly 
gonadotoxic. In addition, multi-drug regimens may have a cumulative toxic effect on 
reproductive function (138). Damage to the ovaries causes follicle loss and may result 
in premature ovarian insufficiency (POI). Indeed, impaired fertility in childhood 
cancer survivors (CCS) has been described (139). In several studies, survivors of 
childhood haematological and solid tumours had high follicle stimulating hormone 
(FSH) levels and amenorrhoea, indicative of ovarian failure (140-143). However, most 
studies have described ovarian function in small groups, in which the extent of damage 
to the ovarian reserve was not predictable (140-142). Despite the presence of high FSH 
levels and amenorrhoea after chemotherapy, pregnancies in CCS have been reported as 
well (144, 145). Hence, FSH levels or menstrual cyclicity after cancer treatment do not 
seem to be predictive of the chance to conceive (140, 144). 
Recently, serum anti-Müllerian hormone (AMH) was established as a novel marker 
of ovarian reserve (80). Results from pre-clinical studies confirmed the role of AMH 
in human folliculogenesis, i.e. inhibition of initial recruitment and attenuation of 
FSH sensitivity (146). Clinical studies showed that the number of antral follicles and 
age correlate well with serum AMH levels. Moreover, serum AMH levels seem to be 
related to the onset of menopause (83). Furthermore, decrease in AMH levels seems to 
precede changes in conventional parameters associated with peri-menopausal status, 
such as FSH, inhibin B and oestradiol (70, 80). Therefore, serum AMH levels are the 
most reliable marker of ovarian ageing. Furthermore, several studies have described 
AMH as a predictor of ongoing pregnancy after assisted reproductive treatment (60, 
147-149). Finally, in contrast to gonadotrophins, AMH levels were unaffected by cyclic 
variations or the use of oral contraceptive pills (OCPs) (128, 129).  
Although AMH has been described as a useful marker of ovarian reserve in 
survivors of cancer diagnosed at adult age, data on the value of AMH in adult survivors 
of childhood cancer are scarce (135, 136, 150). Recently, in two studies AMH was 
measured in survivors of childhood Hodgkin lymphoma (n = 32), haematological 
malignancies and solid tumours (n = 21) (116, 151). These studies confirmed that, 
in CCS with regular menstrual cycles, serum AMH levels were indicative of limited 
ovarian reserve, whereas FSH, oestradiol and inhibin B levels were not different from 
healthy controls (151). So far, no studies are available on AMH levels in large cohorts of 
CCS. In the current study, ovarian reserve was assessed in a large single centre cohort 
of 185 CCS by measuring serum AMH levels and comparing them with controls.  
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materials and metHods
subjects
The study was approved by the local medical ethical review board. Written informed 
consent was obtained from all participants. These adult female CCS had been treated 
at the Erasmus MC – Sophia Children’s Hospital from October 1958 until December 
2000. Participants were 18 years and younger at time of diagnosis and had finished 
treatment at least 5 years prior to study inclusion. At the time of follow-up they 
were  17 to 50 years old and in complete remission. Participants were recruited at the 
outpatient clinic during follow-up of long-term effects of cancer treatment. Because 
of possible hypothalamic-pituitary-axis dysfunction, survivors of brain tumours were 
excluded from this study. Details on cancer treatment were recorded, including type 
and cumulative doses of chemotherapy, site, field, cumulative dose of radiotherapy, 
type of surgery and/or conditioning regimen prior to stem-cell transplantation, as 
well as complications and relapse. Subsequently, a general health screening, including 
extensive history taking and physical examination, was performed. Serum samples 
were taken randomly during the menstrual cycle, in pregnant survivors as well as in 
survivors taking OCPs.
A cohort of 42 women without a history of cancer and with a regular menstrual 
cycle was recruited as controls, as described previously (80). Briefly, inclusion criteria 
were age between 20 and 35 years, normal body mass index (BMI) (between 19 and 
26 kg/m2) and regular menstrual cycle length between 26 and 31 days. In addition, 
these women were healthy and were all proven fertile. They did not have any endocrine 
disease and did not use any medication, OCPs or hormonal treatment. Blood samples 
were drawn during the early follicular phase. 
Hormone assays
AMH was measured in controls using the Immunotech-Coulter assay and in survivors 
using an in-house double-antibody enzyme-linked immunosorbent assay (ELISA) (76, 
80). The values from the in-house ELISA assay were adjusted ( ÷ 2.145) for comparison 
with the Immunotech-Coulter assay. Intra- and interassay coefficients of variance were 
<10% and <5% in the in-house ELISA assay and <5% and 8% in the Immunotech-Coulter 
assay (79, 80). Fluorescence–based immunoassays were used to measure FSH levels 
(Immulite, Diagnostic Products Corp., Los Angeles, CA, USA). A radioimmunoassay 
was used to assess oestradiol serum levels (Diagnostic Products Corp., Los Angeles, 
CA, USA). Intra- and interassay coefficients of variance were <3% and 8% for FSH, 
<5% and 7% for oestradiol. Serum Inhibin B levels were determined using an enzyme-
linked immunoassay (Oxford Bio Innovation, Oxford, United Kingdom). Intra- and 
interassay coefficients of variation were less than 9% and 15%.
data analysis
Non-parametric tests were used to compare general characteristics between survivors 
and controls. Chi-square tests and non-parametric tests were used to compare 
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participants and non-participants. Univariate analysis of covariance (ANCOVA) was 
performed to compare AMH in survivors and controls. Likewise, subgroup analysis was 
performed. Survivors were grouped according to their diagnosis or treatment received. 
Multi-drug chemotherapy regimens containing cyclophosphamide, procarbazine or 
ifosfamide were referred to as “chemotherapy with alkylating properties”. Correlations 
between AMH and total cumulative dose of chemotherapy were determined using 
ANCOVA for categorical parameters (more or less than 3 mechlorethamine, 
vincristine, procarbazine and prednisone [MOPP] cycles) and partial correlation 
analysis for continuous variables (total cumulative dose of cyclophosphamide or 
ifosfamide). Similarly, the correlation between AMH and the total dose of radiation 
(Gray [Gy]) was assessed using partial correlation analysis. In addition, subanalysis 
was performed using ANCOVA in subgroups according to treatment before or after 
menarche, cyclicity and pregnancy rate. Oligomenorrhoea was defined as a cycle 
interval longer than 35 days, but shorter than 6 months. Amenorrhoea was defined 
as an interval between cycles of longer than 6 months. All outcome parameters were 
adjusted for age differences. Survivors with AMH <0.1μg/L were analysed separately 
and their characteristics were compared with survivors with AMH >0.1μg/L. Data were 
presented as the median and range. 
For the 42 control women, linear regression of age on log-transformed AMH values 
was performed and 90% prediction limits were calculated. The formula: AMH*exp(3.47-
0.102*age) was used to calculate the mean decline in AMH levels in controls, adjusting 
for increasing age. The 10th and 90th prediction intervals for decline of AMH levels 
were calculated using the formula: AMH*exp(3.47-0.102*age) ± 1.23*√ (1.013 + ((age-
30.48)/38.45)2)), with adjustment for increasing age. For graphical display, results of 
the linear regression were back-transformed. Statistical analysis was performed using 
Statistical Package for Social Sciences 12.0 (SPSS Inc, Chicago, IL). A P value < 0.05 
indicates statistical significance.  
results
survivors
The total cohort of CCS included 238 women, of whom 25 withdrew from participation. 
Out of 213 eligible subjects, serum AMH levels were measured in 185 (185/238; 78%) 
survivors (Figure 3.2.1). In 21% (n = 38) of the 185 CCS samples for measurement of 
FSH, oestradiol and inhibin B levels were drawn during the early follicular phase of 
the menstrual cycle and thus were useful for analysis. Median age at diagnosis was 8.2 
years (range 0.3 - 15.8 years) in survivors who discontinued follow-up and those in 
whom serum AMH levels were not available, and was similar in participants (median 
5.8 years; range 0.1 – 16.8 years; P = 0.82). Neither the type of malignancies (P = 0.14), 
nor the frequency of relapse (13% vs. 12%; P = 0.54), the number of survivors receiving 
chemotherapy (93% vs. 87%; P = 0.22) or radiotherapy (36% vs. 32%; P = 0.73) were 
different between participants and non-participants. 
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diagnosis and treatment
In participants, median age at time of treatment was 5.8 years (range 0.1 – 16.8 years) 
and median age at time of AMH assessment was 25.5 years (range 17.0 – 47.4 years). 
Twenty-four (13%) survivors were in second complete remission after relapse. Seventy-
seven survivors had been treated for acute lymphoblastic leukaemia (ALL) or non-
Hodgkin lymphoma (NHL). These survivors were assigned to the “leukaemia group”. 
Eight survivors were diagnosed with acute myeloid leukaemia (AML). Fifteen survivors 
with Hodgkin lymphoma (HL) were included, of whom 14 have been described earlier 
as part of a multi-centre study from our group (151). Since our objective was to analyse 
our total cohort of female survivors, these women were also included in the present 
185/238 survivors (77%):  
serum AMH levels available for analysis
No CT, no RT 
n = 10 (5%)
CT without alkylating agents
n = 69 (38%) 
RT only
n = 3 (2%) 
+ RT on other sites 
n = 49/182 (27%)
≥3 MOPP cycles 
n = 9/182 (5%)
<3 MOPP 
or EBVD cycles  
n = 6/182 (3%)
+ RT on 
abdomen/TBI 
n = 14/182 (8%)
CY cycles
n = 67/182 (37%)
Ifos cycles 
n = 8/182 (4%)
CT with alkylating agents
n = 100 (55%) 
CY + Ifos cycles 
n = 10/182 (5%)
USO/BSO
n = 3 *
238 survivors eligible 
(100%)
232 responders (97%)
213 survivors (90%)
6 non-responders (3%) 
5 deceased during follow-up (2%)
6 refused participation (3%) 
3 emigrated (1%) 
3 disabled after therapy (1%) 
2 patients > 50 years (1%) 
Figure 3.2.1  
Figure 3.2.1. Flow diagram of subjects. 
CT = chemotherapy; RT = radiotherapy; USO = unilateral salpingoophorectomy; BSO = bilateral 
salpingoophorectomy; MOPP = mechlorethamine, vincristine, procarbazine and prednisone; 
EBVD = epirubicin, bleomycin, vinblastine and dacarbazine; TBI = total body irradiation; CY = 
cyclofosfamide; Ifos = Ifosfamide
 * = not included in the analysis.
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study. The remaining subgroups consisted of 17 survivors of neuroblastoma (NBL), 25 
survivors of sarcoma, 28 with a nephroblastoma, 9 with Langerhans cell histiocytosis 
(LCH), 3 with a germ cell tumour, 1 with a hepatoblastoma and 1 with a carcinoid 
tumour. Three survivors diagnosed with Burkitt lymfoma (n = 1) and germ cell tumours 
(n = 2) were treated with chemotherapy and an unilateral salpingoophorectomy or 
bilateral salpingoophorectomy. Since their ovarian reserve was reduced by surgery, 
these three survivors were analysed separately. Finally, excluding these three subjects, 
182 survivors were analysed (Table 3.2.1). 
CCS Serum AMH (μg/L) P
All subjects included in analysis N = 182 (%) 1.7 (<0.1 – 19.9) 0.57
Diagnosis
Leukemia group (ALL, NHL) 77 (42%) 2.2 (<0.1 – 14.1) 0.50
AML 8 (4%) 0.5 (<0.1  – 5.1) 0.17
Hodgkin’s Lymphoma 15 (8%) 0.8 (<0.1  – 12.1) 0.32
Neuroblastoma group 17 (9%) 1.9 (0.1 – 6.2) 0.28
Sarcoma group 25 (14%) 1.5 (<0.1  – 19.9) 0.15
Wilms tumour 28 (15%) 1.5 (<0.1 – 13.1) 0.38
LCH 9 (5%) 4.2 (1.6 – 11.5) 0.011
Other tumours 3 (2%) 3.7 (2.0 – 6.4)* -
Time of treatment
Treated prior to menarche 114 (63%) 1.7 (<0.1 – 19.9) 0.72
Treated after menarche 31 (17%) 1.4 (<0.1 – 12.1) 0.94
Age of menarche unknown 37 (20%) 1.9 (<0.1 – 12.6) † -
Menstrual cycles
Regular cycles 33 (18%) 2.3 (<0.1 – 13.1) 0.37
Oligo- or amenorrhoea 28 (15%) 1.2 (<0.1 – 14.1) 0.13
OCPs 98 (54%) 1.8 (<0.1 – 19.9) 0.72
HRT 5 (3%) <0.1 (<0.1 – 1.0)* -
Gravida 4 (2%)   0.9 (0.4 – 3.7)* -
Data on menstrual cycles missing 14 (8%)    1.8 (<0.1 – 6.7 † -
Table 3.2.1. Serum AMH levels in childhood cancer survivors (CCS) as compared with 42 
control subjects. 
P values indicate differences in serum AMH levels (in μg/L) between survivors and controls by 
ANCOVA, adjusting for age differences. Median AMH levels in controls was 2.1 μg/L, range 
(0.1 – 7.4μg/L). 
Values are absolute numbers (proportions %) or medians (range). 
ALL = acute lymphoblastic leukemia; NHL = non-Hodgkin lymphoma; AML = acute myeloid 
leukemia; LCH = Langerhans cell histiocytosis; OCPs = oral contraceptive pills; HRT = 
hormonal replacement therapy. 
* =  Analysis was not performed because of small number of patients.  † = Analysis was not 
performed because data were missing.
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Sixty-three survivors (63/182; 35%) received chemotherapy and radiotherapy. 
Fourteen of these 63 women (22%) received alkylating chemotherapy as well as 
radiotherapy on their whole body or abdomen (Figure 3.2.1). Two of the nine survivors 
of LCH had received radiotherapy on the neck or face and eight were treated with 
chemotherapy. Survivors of AML were analysed separately from the ‘leukemia’ group, 
since their treatment is radically different: five of the eight AML survivors received 
stem cell transplantation after a conditioning regimen of alkylating chemotherapy and 
total body irradiation (TBI). Most survivors (63%) had been treated before they had 
reached menarche, 17% were treated after menarche and in 20% of cases the age of 
menarche was unknown. At the time of inclusion, 4/182 survivors (2%) were pregnant. 
Thirty-three survivors (33/182; 18%) had regular menstrual cycles, whereas 28/182 
(15%) survivors suffered from oligomenorrhoea or amenorrhoea. In 14/182 survivors 
(8%) data on menstrual cycle at the time of screening were not available. All other 
survivors used OCPs (98/182; 54%) or hormonal replacement therapy (5/182; 3%) at 
the time of follow-up (Table 3.2.1). Median time of follow-up was 18.1 years (4.1 – 43.2 
years). 
endocrine profiles
Median serum AMH levels in the 182 survivors were within the normal range after 
adjustment for age (P = 0.57). There were no differences in AMH levels between 
subgroups classified according to malignancy and controls, except for survivors of 
LCH in whom serum AMH was higher than in controls (P = 0.011) (Table 3.2.1). 
AMH concentrations in survivors treated before menarche were not different from 
those in controls (P = 0.72). Similarly, AMH levels in survivors treated after menarche 
were within the normal range (P = 0.94) (Figure 3.2.2A). In addition, after excluding 
survivors treated with TBI or abdominal radiotherapy and survivors treated with 
three or more procarbazine containing cycles, serum AMH concentrations were not 
different in survivors treated prior to or after menarche (2.0 vs. 2.1 μg/L; P = 0.88). 
AMH levels were not different in survivors with regular cycles, oligomenorrhoea or 
amenorrhoea, or in those taking OCPs and controls (2.3 μg/L, 1.2 μg/L, 1.8 vs. 2.1 
μg/L, respectively). In the 5 survivors taking hormonal replacement therapy, which 
was prescribed because of secondary amenorrhoea, median AMH level was <0.1 (<0.1 
– 1.0 μg/L). Moreover, no differences were observed in AMH concentrations between 
survivors with regular cycles and oligomenorrhoea or amenorrhoea (2.3 vs. 1.2 μg/L; 
P = 0.43) (Figure 3.2.2B) (Table 3.2.1). Finally, no differences were observed in AMH 
levels in multipara survivors or nullipara survivors versus controls (1.5; 1.7 vs 2.1 μg/L; 
P = 0.51; P = 0.78). Unfortunately, in survivors who were pregnant at time of inclusion, 
cycle information or gonadotrophin levels prior to their pregnancy were not available. 
No correlation was observed between the duration of follow-up and serum AMH 
concentrations (P = 0.69). 
Serum AMH levels were significantly lower in survivors who received radiotherapy 
on the abdomen, pelvis, sacrum or their total body (<0.1 vs. 2.1 μg/L; P < 0.001) than 
in controls, whereas survivors irradiated on other parts of their body had normal 
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Figure 3.2.2. Serum AMH levels in subgroups of survivors versus 10th, 50th and 90th percentile 
of AMH levels in controls (solid lines). A. Survivors treated prior to (black dots) or after 
(open squares) menarche. B. Survivors with regular menstrual cycles (black dots) or oligo- 
or amenorrhoea (open squares). C. Survivors treated total body irradiation or abdominal 
radiotherapy (black dots), more than 3 MOPP cycles (grey squares) or other treatment regimen 
(open dots).
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AMH levels (1.5 μg/L(<0.1 – 11.4); P = 0.52) (Figure 3.2.2C). In 25 survivors of ALL, 
irradiated on the cranium, AMH levels were similar to controls (P = 0.96) and to ALL-
survivors without cranial radiotherapy (2.3 vs. 1.5 μg/L; P = 0.87) (Table 3.2.2). The 
cumulative radiation dose administered on the cranium varied between 18 and 49 Gy. 
It varied from 10 to 70 Gy when administered on the abdomen and was not correlated 
with serum AMH concentrations (P = 0.54).
In survivors treated with chemotherapy AMH concentrations were comparable 
with those in controls (1.8 vs. 2.2 μg/L; P = 0.38). Although median AMH levels in 
the whole group of HL-survivors were normal (median 0.8 μg/L; P = 0.32), they were 
significantly lower after three or more MOPP cycles as compared with controls (0.5 
CCS Serum AMH (μg/L) P
All subjects included in analysis N = 182 (%) 1.7 (<0.1 – 19.9) 0.57
Treatment
Patient with USO* 1* 8.9* -
Patient with BSO* 2* <0.1 * -
Surgery (no USO/BSO), no CT, no RT 10 (5%) 3.3 (0.1 – 11.9) 0.029
RT 3 (2%) 0.2 (<0.1 – 9.0)† -
CT without alkylating agents 69 (38%) 1.7 (<0.1 – 14.1) 0.30
CT containing alkylating agents 100 (55%) 1.8 (<0.1 – 19.9) 0.95
Type of alkylating CT and/or RT
≥3 MOPP cycles 9 (5%)   0.5 (<0.1 – 3.6)‡ 0.004
<3 MOPP cycles or EBVD cycles 6 (3%) 3.2 (<0.1 – 12.1) 0.30
Cyclophosphamide cycles 67 (37%) 1.5 (<0.1 – 12.7) 0.63
(Cyclophosphamide+)Ifosfamide cycles 18 (10%) 3.2 (<0.1 – 19.9) 0.08
CT + RT on abdomen or TBI 14 (8%) <0.1 (<0.1 – 2.5) <0.001
CT + RT other sites 49 (27%) 1.5 (<0.1 – 11.4) 0.52
ALL 64 0.29 
CT with cranial RT 25 2.3 (<0.1 – 7.3) 0.96
CT without cranial RT 39 1.5 (<0.1 – 14.2) 0.62
Table 3.2.2.  Serum AMH levels in childhood cancer survivors according to treatment as 
compared with 42 control subjects.
P values indicate differences in serum AMH levels (in μg/L) in survivors and controls, by 
ANCOVA, adjusting for age differences. Median AMH levels in controls was 2.1 μg/L, range 
(0.1 – 7.4μg/L). 
Values are absolute numbers (%) or medians (range). USO = unilateral salpingoophorectomy; 
BSO = bilateral salpingoophorectomy; CT = chemotherapy; RT = radiotherapy; MOPP = 
mechlorethamine, vincristine, procarbazine and prednisone; EBVD = epirubicin, bleomycin, 
vinblastine and dacarbazine; TBI = total body irradiation. 
* = Patients were not included in analysis because ovarian reserve was compromised by ovarian 
surgery. †  = Analysis was not performed because of small number of patients. ‡  = ANCOVA 
between CCS treated with ≥3 MOPP cycles vs. CCS treated with <3 MOPP cycles or EBVD 
cycles: P = 0.04
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vs. 2.1 μg/L; P = 0.004) and compared with HL-survivors treated with epirubicin, 
bleomycin, vinblastine and dacarbazine (EBVD) (0.5 vs. 3.2 μg/L; P = 0.04) (Figure 
3.2.2C). No significant correlations were observed between serum AMH levels and 
total cumulative dose cyclophosphamide or ifosfamide (P = 0.63; P = 0.08, respectively). 
In the only patient treated with an unilateral salpingoophorectomy, serum AMH was 
8.9 μg/L. In both survivors who had a bilateral salpingoophorectomy, serum AMH 
levels were undetectable. Survivors treated with non-gynaecological surgery without 
any chemotherapy or radiotherapy (n = 10) had higher AMH levels than controls (P = 
0.029) (Table 3.2.2).
In 27% (49/182) of our survivors, AMH levels were lower than the 10th percentile 
of normal values. In only 11 of these 49 survivors, FSH, oestradiol and inhibin B levels 
were evaluable: FSH levels were within normal ranges (5.0 vs. 6.2 U/L; P = 0.17), 
whereas inhibin B levels were lower than in controls (9 vs. 113 ng/L; P <0.001). Even 
after excluding survivors older than 35 years, 41 (23%) survivors had AMH levels 
below the 10th percentile. Recently, serum AMH levels  ≥1.4 μg/L were described as 
predictive for ongoing pregnancy after in vitro fertilization (IVF) or intracytoplasmic 
sperm injection (ICSI) treatment cycles in healthy, but infertile women (148). Since this 
cut-off value was assessed with an assay comparable to the Immunotech-Coulter assay 
used in our study, the cut-off value was applied to our cohort of survivors. In 79/182 
(44%) women serum AMH was lower than this threshold value. These 79 survivors 
were significantly older than the group survivors with AMH levels ≥1.4 μg/L (median 
27 vs. 25 years; P = 0.02). However, their age ranged between 17 and 47 years, which 
was similar to the range in the younger group (16 – 46 years). 
The group of women with AMH levels <0.1μg/L was compared with the remaining 
group of survivors (Table 3.2.3). Women with undetectable AMH levels were 
significantly older at diagnosis (P = 0.03). At follow-up, they had significantly more 
irregular menstrual cycles and received more hormonal replacement therapy because 
of secondary amenorrhea (P <0.001). In addition, in this group, more women had 
received radiotherapy, especially on their whole body or abdomen, than survivors with 
AMH levels >0.1μg/L (P <0.001) (Table 3.2.3).   
disCussion 
Due to increased survival rates, more CCS may tend to delay childbearing, as observed 
in the general population (152). In healthy women older than 35 years, depletion of 
the primordial follicle pool is accelerated and the chances of conceiving spontaneously 
are decreased (22). In CCS, follicle loss may be even more accelerated due to gonadal 
damage caused by cancer treatment. Consequently, in some cancer survivors, 
reproductive function will be more compromised as compared with controls. Although 
AMH concentrations in the whole cohort of survivors were similar to those in controls, 
in 27% of our survivors AMH levels were lower than the 10th percentile of controls. 
Serum AMH levels are the most sensitive marker of ovarian reserve. Low AMH levels 
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All CCS
n = 182
AMH <0.1 
μg/L
n = 17
AMH >0.1 
μg/L
n = 165 P
Age at treatment (years) 5.8
(0.1 – 16.8)
10.4 
(1.1 – 16.1)
5.3 
(0.14 – 16.8)
<0.05
Age at follow-up (years) 25.5
(16.9 – 47.4)
28.0 
(18.0 – 47.4)
25.9 
(16.9 – 46.2)
NS
Menstrual cycle (n; %)
Regular 33 2 (6%) 31 (94%) <0.001
Oligomenorrhea/amenorrhea 28 4 (14%) 24 (86%)
Oral contraceptive pills 98 5 (5%) 93 (95%)
Hormonal replacement therapy 5 4 (80%) 1 (20%)
Data not available 15 2 (13%) 13 (87%)
Time of treatment (n; %)
Prior to menarche 114 5 (4%) 109 (96%) <0.01
After menarche 31 7 (23%) 24 (77%)
Diagnosis (n; %)
Leukemia group (ALL, NHL) 77 4 (5%) 73 (95%) <0.05
AML 8 4 (50%) 4 (50%)
M Hodgkin 15 3 (20%) 12 (80%)
Sarcoma 25 3 (12%) 22 (88%)
Wilms tumour 28 3 (11%) 25 (89%)
Treatment (n; %)
Chemotherapy alone or radiotherapy 
alone
109 2 (2%) 107 (98%) NS
Chemotherapy and radiotherapy 63 15 (24%) 48 (76%) <0.001
≥3 MOPP 9 2/15 (13%) 11 (87%) NS
Radiotherapy on abdomen or total body 14 9 (64%) 5 (36%) <0.001
Table 3.2.3. Patient characteristics in survivors with serum AMH < 0.1μg/L as compared 
with survivors with serum AMH >0.1μg/L. P values indicate differences in characteristics in 
survivors with serum AMH < 0.1μg/L as compared with the remaining group of survivors 
with serum AMH >0.1μg/L by Chi-square test (categorical variables) or Mann Whitney-U test 
(continuous variables). For survivors with AMH serum <0.1μg/L, numbers per subgroup and 
percentage of the total number of CCS (n = 182) are given. 
ALL = acute lymphoblastic leukemia; NHL = non-Hodgkin lymphoma; AML = acute myeloid 
leukemia. 
MOPP = mechlorethamine, vincristine, procarbazine and prednisone. 
are predictive for poor ovarian response in IVF treatment cycles (70). Thus it may 
be concluded that low AMH levels and low ovarian response to ovarian stimulation 
are correlated with ovarian ageing and, hence, with decreased fertility (59, 80, 96). 
Therefore, we postulated that women are at risk of decreased fertility, based on low 
ovarian reserve, and consequently, these women may have low chances of pregnancy 
after assisted reproductive techniques. Accordingly, their chances of spontaneous 
pregnancy may be even lower. Moreover, taking into account the previously described 
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threshold value, indicating poor outcome of IVF treatment, only 56% of our survivors 
would be likely to have an ongoing pregnancy after IVF or ICSI (148). Furthermore, 
not only the elder, but also survivors younger than 20 years had AMH levels below 
this threshold. Hence, despite normal AMH levels, chances of both future spontaneous 
pregnancy and pregnancy after assisted reproductive treatment may be impaired in the 
majority of our CCS. It may be premature to apply a cut off value, since this has not 
been validated in the population under study. However, counseling on fertility is an 
important topic, especially for the youngest survivors with low AMH levels. Although 
these young women may not yet think about their future, in terms of reproduction, 
they should be discouraged from postponing their first pregnancy until an age at which 
their ovarian reserve is depleted. Until now, cancer survivors can only be counseled 
based on a limited amount of data from currently available reports which include 
cut-off values (60, 147-149, 153). Most studies used a discriminating cut-off value 
twice as high than the one applied to our cohort (60, 147, 149). A higher cut-off value 
would result in an even worse outcome for our survivors. However, results of different 
studies should be interpreted with care, since international standards for an AMH 
assay are lacking. In addition, these cut-off levels have been described in women with 
infertility and the number of normal fertile women, who may have AMH levels lower 
than this cut-off level is unknown. Unfortunately, the number of our control subjects 
was limited to 42 and 11 of them had AMH levels lower than 1.4 ng/mL. Nevertheless, 
there seems to be a large variation in serum AMH levels in normal women, reflecting 
the large variation in their reproductive status and age of menopause (83). Therefore, 
it can be hypothesized that normal women, including our controls, will have AMH 
values within the normal range for their age. 
To our knowledge, this is the first study to describe ovarian reserve in a large cohort 
of adult CCS using AMH. Until now, the few available studies on ovarian reserve in 
large cohorts of CCS have defined ovarian failure as amenorrhoea or failure to conceive, 
while endocrine profiles were not assessed (47, 139, 143, 154, 155). Moreover, studies 
using gonadotrophin levels as a parameter of gonadal reserve after cancer therapy 
were performed in small groups of survivors (140, 142, 156). A further limitation of 
these studies is that increased FSH levels, amenorrhoea and subfertility are present at 
the very end of the reproductive life span (22). In the present study, the majority of 
survivors used OCPs and  consequently, gonadotrophin levels or menstrual cyclicity 
were not informative concerning ovarian function. Nevertheless, in clinical practice, 
survivors should be counseled regarding their future chances of conception. Therefore, 
survivors with reduced reproductive potential should be identified at a stage in their 
fertile life span when interventions such as fertility preservation are still feasible. AMH 
provides an opportunity for  survivors to be counseled on their level of fertility. Indeed, 
a recent study demonstrated that a healthy woman with low serum AMH for her age is 
likely to reach menopause before the median age of 51 years (83). Hence, serum AMH 
levels may be related to the age of menopause in healthy women (83). In another study, 
healthy pre- and perimenopausal women were followed for six years. Their serum 
AMH levels were undetectable five years prior to their final menstrual period (82). It 
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was concluded that low or non-detectable AMH levels were predictive of menopausal 
transition, whereas serum inhibin B and FSH levels were less predictive (82). Hence, 
these studies indicate that our survivors with AMH levels lower than their age-matched 
controls will probably reach menopause before the average 51 years. 
Until recently, the extent of gonadal damage was thought to depend on the age 
of the patient at the start of therapy, the type of treatment and the dose (136). In 
this study no differences were observed in the number of women treated with 
chemotherapy and radiotherapy between survivors with AMH<0.1μg/L and those 
with AMH>0.1μg/L. However, in the first group significantly more women had 
been treated with TBI or abdominal radiotherapy. Indeed, only AML survivors who 
had received TBI had undetectable AMH levels. Likewise, only those Hodgkin’s 
lymphoma-survivors who had been treated with more than three MOPP cycles had 
low AMH levels, as described previously  (151). These results indicate that type of 
treatment is the most important predictive factor for residual ovarian function after 
treatment, rather than age at treatment. Neither the menarcheal state, nor the total 
cumulative dose of cyclophosphamide seemed to influence the extent of damage to the 
ovaries found in our study. Many studies have shown that administration of alkylating 
agents was an independent risk factor for POI  (143, 144), but a direct correlation 
between the dose of chemotherapy and the endocrine parameters of ovarian reserve 
was not observed (124, 143, 154). Indeed, in our study, the total cumulative dose of 
cyclophosphamide did not correlate with AMH levels. Presumably, the gonadotoxic 
effect of cancer treatment is determined by different agents (138). Furthermore, 
it could be hypothesized that other factors, such as genetic predisposition may be 
involved. The presence of a single nucleotide polymorphism in the AMH gene or the 
AMH type II receptor gene may result in a slightly faster depletion of the ovarian 
reserve (75). Cancer treatment may be an additional risk factor for POI in these 
women. Therefore, long-term follow-up and sequential AMH measurements will be 
needed to confirm the early age of menopause in CCS.
In conclusion, this is the first study in which AMH was used to identify subgroups 
of CCS highly at risk for POI, i.e. survivors treated with abdominal irradiation, total 
body irradiation or three or more MOPP cycles. Especially in these survivors, options 
for fertility preservation should be considered before starting therapy. A substantial 
part of our survivors had AMH levels below the 10th percentile and may have POI. 
In addition, a high proportion of CCS is at risk for poor chances of pregnancy after 
assisted reproductive treatment. Obviously, chances of spontaneous pregnancy will be 
even lower, especially if survivors postpone their first pregnancy until the third decade.
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abstraCt 
Background: The number of childhood cancer survivors has dramatically increased and 
consequently, an increasing number of survivors may now wish to conceive. Recently, 
several studies have described that previous treatment with abdominal radiotherapy 
may increase the risk of adverse pregnancy outcome. 
Methods: We conducted a retrospective single centre cohort study of childhood 
cancer survivors with a singleton live birth between January 2000 and December 2005. 
Pregnancy outcome was compared with data from the Netherlands Perinatal Registry, a 
nationwide database of pregnancy outcome parameters of all births in the Netherlands 
registered by midwives, obstetricians and paediatricians. 
Results: Data were available on 40 survivors and 9.031 controls. Median age at diagnosis 
was 6.9 years (range 0.1 – 16.8 years). The median interval between diagnosis and date 
of delivery was 21.6 years (range 7.4 – 36.1 years). In the whole cohort, pregnancy 
outcome was not different between survivors and controls. However, survivors treated 
with abdominal radiotherapy delivered preterm and had post-partum haemorrhage 
(mean gestational age in survivors = 34.9 weeks versus 39.2 weeks in controls, P = 
0.001; 33% in survivors versus 5% in controls, P = 0.007, respectively). The offspring 
of survivors had normal birth weight after adjustment for gestational age (mean birth 
weight in offspring of survivors 2,503 g versus 1,985 g; P = 0.22). 
Conclusion: Childhood cancer survivors irradiated to the abdomen have an earlier 
delivery and higher incidence of postpartum haemorrhage. This stresses the need for 
close monitoring of the delivery, including inpatient perinatal care, in this group of 
childhood cancer survivors. 
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introduCtion
As a result of dramatic improvements in survival of childhood cancer, the number of 
adult women that have received cancer therapy during their childhood or adolescence 
will increase (157). Consequently, an increasing number of survivors will reach an 
age at which they wish to have children. Many uneventful pregnancies have been 
reported in childhood cancer survivors (158-161). However, previous studies by our 
group suggested that ovarian reserve was impaired in cancer survivors (150, 151, 
162). In accordance, recent studies have proposed that these women may encounter 
problems while trying to conceive, which has recently been illustrated in a large report 
of the Childhood Cancer Survivor Study (163, 164). Moreover, an increased risk of 
miscarriage, preterm delivery and offspring with low birthweight has been recognized 
as a serious problem in at least subsets of cancer survivors. Hence, studies on pregnancy 
outcome have shown conflicting results (161, 165-174).  The availability of information 
on pregnancy outcome in childhood cancer survivors may be biased; reporting on 
adverse pregnancy outcome may be more challenging than describing successful 
pregnancies. In addition, so far, results were based on small series of survivors and 
never compared with population-based control settings (159). 
Recent studies on pregnancy outcome in childhood cancer survivors have recruited 
healthy siblings of these survivors as controls (167, 168, 170, 171, 173). In the control 
group of healthy siblings, the number of unsuccessful pregnancy outcomes may be lower 
due to recall bias. Consequently, the risk of unfavourable outcome in survivors may seem 
higher than in their healthy sibling controls. In addition, most studies on pregnancy 
outcome in female cancer survivors have focused mainly on neonatal outcome, such as 
stillbirth, birthweight and congenital malformations (145, 154, 170, 171). 
 To our knowledge, the current study is the first to describe pregnancy outcome 
in a single centre cohort of female childhood cancer survivors compared to outcome 
parameters of a nationwide perinatal database.
materials and metHods
subjects
Childhood cancer survivors from the Erasmus MC - Sophia Children’s Hospital in 
Rotterdam were included, if they had a singleton live birth between January 2000 and 
December 2005. At inclusion, they were at least 18 years old and at least 5 years after 
discontinuation of cancer treatment. Participants were recruited at the out-patient clinic 
for follow-up of long-term effects of childhood cancer treatment. Thirty-five women 
had participated in a previous study by our group (162). Details on disease and cancer 
treatment were recorded, including type and cumulative doses of chemotherapy, as well 
as site, field and cumulative dose of radiotherapy, and, if applicable, type of surgery. 
In addition, data on pregnancy outcome, delivery and possible complications during 
pregnancy or during delivery were collected by extensive history taking. Moreover, 
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these self-reported data were completed by and checked with data retrieved from the 
national registry of perinatal data, the Netherlands Perinatal Registry (http://www.
perinatreg.nl/home_english). This registry contained data on all pregnancies, deliveries 
and neonatal outcome in the Netherlands between January 2000 and December 2005 
and had been provided by medical professionals, i.e. midwives, obstetricians and 
paediatricians, who were responsible for the women during pregnancy, delivery, birth 
and the post-natal period. 
Control subjects were selected from the Netherlands Perinatal Registry, after 
matching with survivors by parity, year of birth and month and year of delivery. Hence, 
all women in the Netherlands who had a singleton live birth between January 2000 and 
December 2005 were possible control subjects. 
This study was approved by the local medical ethics review board and written 
informed consent was obtained from each participant. 
outcome parameters  
Maternal outcome parameters were the highest diastolic blood pressure measured 
during pregnancy and the prevalence of pre-eclampsia. In offspring, gestational age, 
birthweight, Apgar score, gender and the percentage of congenital malformations were 
analysed. Outcome parameters after delivery were post-partum haemorrhage and the 
prevalence of a manual removal of placenta. Pregnancy-induced hypertension was 
defined by diastolic blood pressure >90 mmHg.  Preterm birth was defined as duration 
of pregnancy less than 37 weeks. Postpartum haemorrhage was defined as more than 
1 litre blood loss within 24 hours after the delivery. In the national registry, birth 
weight was reported in grams and length of gestation in weeks. Apgar scores were only 
available for the assessment carried out 5 minutes after birth. 
statistical analysis
Outcome parameters were compared between controls and survivors using Students’ 
T test for continuous variables or Chi square test for categorical variables. A univariate 
analysis of covariance (ANOVA) was performed to calculate differences between 
subgroups and controls. We expected that besides diagnosis, the type of treatment 
might also be predictive of pregnancy outcome. Therefore, outcome parameters 
were compared between groups allocated according to diagnosis and controls, and 
between groups based on type of treatment and controls. Consequently, in the analysis, 
parameters in the following groups were compared: childhood acute lymphoblastic 
leukaemia/non-Hodgkin lymphoma (ALL/NHL) versus controls (other groups 
allocated according to diagnosis were too small for comparison, see Results), survivors 
treated with radiotherapy to the abdomen versus controls, and survivors treated 
with chemotherapy only versus controls (survivors treated with surgery only were 
omitted from the analysis, since this group was too small, see Results). In the ANOVA 
calculating differences in birth weight, data were adjusted for gestational age. 
Correlations were calculated between the duration of pregnancy and the total dose 
of radiation with a bivariate correlation. Age at diagnosis was correlated with the length 
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of gestation, using a partial correlation after adjustment for parity. Characteristics in 
survivors were presented as median and range. Since the group of controls was very 
large, results of the comparisons between survivors and controls were presented as 
mean and SD. A P value for two-sided tests < 0.05 indicates statistical significance. 
Because of the large sample size of the perinatal registry, these data were provided in 
SAS/Stat software version 9.0 (SAS Institute Inc., Cary, NC, USA). Statistical analysis 
on differences between survivors and controls was therefore performed in SAS/Stat. 
Analyses within the group of childhood cancer survivors only were performed with 
Statistical package for Social Sciences version 15.0 (SPSS Inc., Chicago, IL, USA). 
results
subjects
From the total cohort of 238 female survivors, six women were lost to follow-up. Of 
the 232 eligible women, five had died during follow-up and six refused participation. 
In addition, three women had emigrated and three women were severely disabled, 
and were not able to visit the out-patient clinic. Finally, in the studied cohort of 215 
childhood cancer survivors, 64 women had been pregnant, of whom 40 (n = 40/215; 
18.6%) had a singleton live birth between 1 January 2000 and 31 December 2005. At 
study inclusion, the survivors included in the analysis (n = 40) were significantly older 
than childhood cancer survivors that had not been pregnant (median age 29.9 versus 
23.8 years, respectively; P < 0.001). However, diagnoses and treatment were similar in 
the 40 women included and the excluded survivors (P = 0.44).
At diagnosis, the 40 study subjects were 6.9 years old (median; range 0.1 – 16.8 
years) and their median age at time of delivery was 29.7 years (range 21.4 – 36.8 years). 
The median interval between diagnosis and date of delivery was 21.6 years (range 7.4 
– 36.1 years) and the median interval between end of therapy and date of delivery was 
20.2 years (range 6.9 – 32.5 years). Most women were primiparous (n = 28/40; 70%); 
20% (n = 8/40) had been pregnant for the second time, three women (7.5%) had been 
pregnant three times and one survivor (2.5%) had 5 pregnancies before study inclusion. 
The 40 women were treated for different malignancies; the largest group had 
survived ALL or NHL (the ‘ALL&NHL group’) (Table 3.3.1). Survivors had been treated 
according to standard national and international treatment protocols, containing a 
variety of multiple drug combinations. Therefore, it was not feasible to evaluate the 
effect of each type of chemotherapy on pregnancy outcome parameters. Sixteen women 
had received radiotherapy, six of whom had received radiotherapy to the abdomen (n = 
1) or flank (n = 4) and in one patient data on the exact size of the radiation field could 
not be retrieved. The six survivors who had received radiotherapy to the abdomen 
were referred to as ‘group treated with abdominal radiotherapy’ and at diagnosis their 
median age was 1.1 years (range 0.3 – 5.2 years). The median total cumulative dose of 
radiation given to the 16 irradiated survivors was 25.0 Gray (Gy) (2.0 – 40.0 Gy). This 
dose was 19.8 Gy (2.0 – 26.5 Gy) in the group treated with abdominal radiotherapy. The 
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three women who had been treated with surgery only, were excluded from analysis. 
Table 3.3.1 shows details of diagnosis and treatment. Data on 9.031 control subjects 
was retrieved from the nationwide perinatal database. 
pregnancy outcome 
There were no differences in maternal outcome parameters between the total cohort 
of survivors and controls after matching by parity, year of birth, month and year of 
delivery. Neonatal outcome parameters, such as gender, gestational age, Apgar score 
and the percentage of congenital abnormalities, were not different in children born to 
survivors compared to those born to healthy controls (Table 3.3.2). 
In survivors of the ‘ALL&NHL group’ (n = 17), neither neonatal nor maternal outcome 
parameters were different from those in controls (data shown in the Supplementary 
Table 3.3.3). Other groups based on diagnosis were considered too small for separate 
analysis (Table 3.3.1). In the group treated with abdominal radiotherapy (n = 6), the 
highest diastolic pressure and the percentage of spontaneous vaginal deliveries were 
similar to that of controls (P = 0.80; P = 0.63) (Table 3.3.2). However, the number 
of preterm deliveries was higher in survivors who received abdominal radiotherapy 
than in controls (mean term of delivery in survivors 34.9 weeks versus 39.2 weeks in 
controls, P = 0.001 (Table 3.3.2). Consequently, birthweight in offspring of survivors 
was lower than children of control subjects (mean birth weight 2,503 g versus 3,271 g, 
respectively; P = 0.02). After adjustment for gestational age, birthweight was similar in 
children born to survivors and those born to control subjects (mean birthweight 2,503 
versus 1,985 g, respectively; P = 0.22) (Figure 3.3.1) (175). Birthweight was lower than 
the 50th percentile in  five out of six children born to women who received abdominal 
Diagnosis
Total
n (%)
Treatment
chemotherapy (CT) and/or radiotherapy (RT)
surgery 
onlyCT only
CT+RT to 
abdomen
RT to 
abdomen only
CT + RT 
to CNS
ALL&NHL 17 (42.5%) 9 - - 8 -
Wilms’ tumour 7  (17.5%) 3 3 1 - -
Neuroblastoma 5  (12.5%) 2 2 - - 1
Hodgkin’s lymphoma 4  (10.0%) 2 - - 2 -
Sarcoma 3  (7.5%) 3 - - - -
Germ cell tumour 1 (2.5%) 1 - - - -
LCH 1 (2.5%) 1 - - - -
Other (teratoma, 
carcinoid) 
2 (5.0%) - - - - 2
Total 40 (100%) 21 5 1 10 3
Table 3.3.1. Diagnosis and treatment characteristics. ALL = acute lymphoblastic leukaemia; 
NHL = non Hodgkin lymphoma; LCH = Langerhans cell Histiocytosis; CNS = central nervous 
system. 
60
pregnancy outcome in childhood cancer survivors
3.3
radiotherapy (Figure 3.3.1). Apgar score five minutes after birth was similar in 
offspring of survivors treated with abdominal radiotherapy and offspring of controls (P 
= 0.26) (Table 3.3.2). A significantly larger proportion of survivors had a post-partum 
haemorrhage than controls (33% versus 5%, respectively; P = 0.007). The comparison of 
the number of these 6 survivors and controls needing a manual removal of the placenta 
did not reach statistical significance (17% versus 3%, respectively; P = 0.08). In all 
women treated with radiotherapy, the total dose of radiation was correlated with the 
Controls
(n = 9.031)
Whole cohort 
CCS
(n = 40)
CCS with RT to 
abdomen 
(n = 6/40)
Highest diastolic tension (mmHg) 81.4 (11.7) 81.9 (12.9) 80.8 (14.6)
Preeclampsia
No
Yes
8.991 (98.9%)
40
40 (100%)
0
6 (100%)
0
Delivery
Vaginal: spontaneous 
 Vaginal: assisted delivery 
Secondary caesarean section
Missing
4.928 (55%)
2.746 (31%)
1.296 (14%)
61
21 (55%)
12 (32%)
5 (13%)
2
5 (83%)
1 (17%)
0 
0
Gestational age (weeks) 39.2 (3.0) 38.9 (2.8) 34.9 (4.3)a
Birth weight (grams) 3.271 (714) 3.266 (705) 2.503 (1.026)
Apgar score 
<8
8
9
10
458 (5%)
526 (6%)
2.165 (24%)
5.856 (65%)
0
3 (8%)
10 (25.0%)
27 (68%)
0
1 (17%)
2 (33%)
3 (50 %)
Congenital malformations
No
Yes
Missing
8.834 (98%)
145 (2%)
52
38 (100%)
0
2
6 (100%)
0
0
Gender 
Male 
Female
Unknown
4.727 (52%)
4.301 (48%)
3
19 (48%)
21 (53%)
0
3 (50.0%)
3 (50.0%)
0
Postpartum hemorrhage
No
Yes
Missing
8.232 (95%)
449 (5%)
350
35 (92%)
3 (8%)
2
4 (67%)
2 (33%)a
0
Manual removal of the placenta
No
Yes
Missing 
8.430 (97%)
251 (3%)
350
37 (97%)
1 (3%)
2
5 (83%)
1 (17%)b
0
Table 3.3.2. Parameters in controls, the whole cohort childhood cancer survivors and childhood 
cancer survivors treated with radiotherapy to the abdomen. Data are presented as number (n 
[%)] or mean (SD). CCS = childhood cancer survivors; RT = radiotherapy. 
a P <0.01 
b P = 0.08
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length of gestation (r = 0.67; P = 0.004). However, the dose of radiation administered 
to the abdomen was not correlated with the term of birth (r = 0.46; P = 0.35) (data not 
shown).
Twenty-one women had been treated with chemotherapy only. Their median age at 
diagnosis was 9.9 years (range 0.1 – 15.6 years). No significant differences in maternal 
or neonatal variables were observed between these survivors and controls (data shown 
in the Supplementary Table 3.3.3).
Age at diagnosis was positively correlated with the duration of pregnancy (r = 0.48, 
P = 0.006) in the whole cohort. However, this correlation no longer reached statistical 
significance after exclusion of the 6 survivors treated with abdominal radiotherapy (r 
= - 0.20; P = 0.34). Since these 6 women had been treated at the median age of 1.1 years 
(range 0.3 – 5.2 years), age at diagnosis and pregnancy duration were not significantly 
correlated (r = 0.59, P = 0.30) in the group treated with abdominal radiotherapy.  
Figure 3.3.1 
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Figure 3.3.1. Birth weight (in grams) in offspring of childhood cancer survivors in population-
based birth weight curves per gestational age (in weeks). 
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Chapter 3.3 
Figure 3. 1. Birth weight (in grams) in offspring of childhood cancer survivors in population-based birth 
weight curves per gestational age (in weeks).  
  2.3th and 97.7th percentile 
  10th and 90th perc ntile 
                     5 th percentile 
▲  Offspring of survivors not treated with abdominal radiotherapy (n = 34) 
●  ffs ri g f s r i rs treated with abdominal radiotherapy (n = 6)
 
Table 3.3.1. Diagnosis and treatment characteristics. ALL = acute lymphoblastic leukaemia; NHL = non 
Hodgkin lymphoma; LCH = Langerhans cell Histiocytosis; CNS = central nervous syst m.  
Table 3.3.2. Para eters in controls, the whole cohort childhood cancer survivor  and childhood cancer 
survivors treated with radiotherapy to the abdomen. Data are presented as number (n [%)] or mean (SD). 
CCS = childhood cancer survivo s; RT = radiotherapy.  
a P <0.01  
b  = . 8  
Supplementary table 3.3.3 Parameters in controls, he childhood cancer survivors with ALL or NHL nd 
childhood cancer survivors treated with chemotherapy only. Data are presented as number (n [%)] or mean 
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lymphoma.  
 
 
  
 
 
 
62
pregnancy outcome in childhood cancer survivors
3.3
disCussion  
To our knowledge, this is the first retrospective analysis on pregnancy outcome in a 
single centre cohort of childhood cancer survivors, which compares these data with 
healthy age-matched controls recruited from a nationwide database. In the total cohort 
of childhood cancer survivors, pregnancy outcome was not different from that in the 
general population. However, the current study shows that in the group of survivors 
who had undergone abdominal irradiation, the  frequency of preterm deliveries was 
higher than in controls, as previously reported (167, 169-171, 176). Besides that, the 
frequency of post-partum haemorrhage was also higher than in controls: although our 
findings were based on data of only six survivors, this has not been reported so far 
in childhood cancer survivors. Most of these women received radiation to the flank 
and none of them was irradiated to the pelvis. In addition, these 6 women had been 
treated at a very young age, when the uterus is small. Hence, it may not be expected 
that radiotherapy to the abdomen had caused the adverse pregnancy outcome. Indeed, 
earlier studies showed that abdominal irradiation of at least 20 Gy caused irreversible 
damage to the uterine musculature and blood flow (176). Although scatter radiation 
to the uterus could not be prevented, it is not plausible that the different radiotherapy 
regimens in our 6 survivors have resulted in compromised uterine musculature. 
Possibly, chemotherapy might have damaged uterine structures, resulting in smaller 
uterine volume and hence, restricting uterine distensibility (166).  This finding will 
need to be confirmed in a larger prospective study sample. 
Impaired vascular adaptation to placentation has been associated with pregnancy-
induced hypertension, pre-eclampsia and intra-uterine growth restriction (177, 178). 
Although the severity of pre-eclampsia and its maternal complications may vary 
considerably, women with pre-eclampsia are at risk of preterm birth and children 
small for gestational age (179). We therefore speculated that women previously treated 
with abdominal radiotherapy may also encounter vascular-related problems during 
pregnancy. However, surprisingly, there were no significant differences in diastolic 
blood pressure between survivors and controls. To date, no studies have addressed 
possible hypertension related problems during pregnancy in long-term childhood 
cancer survivors (169). 
It has been assumed that prior to menarche, blood flow through the internal genital 
system is lower than during puberty and the reproductive lifespan (180). Consequently, it 
could be hypothesized that cancer treatment may cause less damage when administered 
prior to menarche. However, in our results, age at diagnosis did not influence the term 
of delivery. Since none of our six survivors had reached menarche at time of abdominal 
irradiation, their pre-menarcheal stage did not seem protective against adverse effects 
of cancer treatment regarding uterine distensibility and contractility. These findings 
confirm that chemotherapy and radiotherapy administered in children may cause 
permanent damage to the uterine musculature, independent of menarcheal stage at 
treatment.
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In contrast, in girls previously treated with total body irradiation it was shown 
that young age at treatment was correlated with smaller uterine volume, assessed at 
young adulthood (165). In that study, controls were childhood cancer survivors treated 
with chemotherapy, but without radiotherapy to the uterus (165). Another recent 
study showed that adult childhood cancer survivors with regular menstrual cycles 
had lower uterine blood flow and smaller uterine volume than age-matched healthy 
controls (166). This illustrates the importance of the design of the current study, in 
which healthy age-matched women were used as controls. In addition, findings of the 
aforementioned studies suggest that a smaller uterine volume may be expected in our 
survivors previously treated with radiotherapy to the uterus. Unfortunately, ultrasound 
data on uterine volume were not available, neither in our survivors nor in controls, but 
the higher frequency of preterm deliveries may reflect the restricted uterine volume in 
irradiated women in our study group.
In the current study, data from the nationwide registry, which were recorded 
by medical professionals, were used as control data. Consequently, recall bias that 
is characteristic of self-report studies was avoided (164, 181, 182). However, in the 
Netherlands Perinatal Registry, only births between 2000 and 2005 were available for 
analysis and hence, matching  for parity, year of birth, month and year of delivery 
resulted in a study group of only 40 survivors. So, despite the solid control cohort, 
only a small sample of survivors was included. In addition, the national registry did 
not document ethnicity. Therefore, our cases and controls could not be matched for 
this parameter, in contrast to previous siblings-control studies (145, 164, 171, 173, 
181, 183, 184). Similarly, neither BMI nor smoking habits were registered in the Dutch 
nationwide database. 
Offspring of our survivors treated with abdominal radiotherapy had a birthweight 
appropriate for gestational age after adjustment for gestational age. Similarly, in 
another recent study, women treated with flank irradiation delivered prematurely and 
consequently, their children had lower birth weight (164, 167). It was concluded that 
childhood cancer survivors were at risk of children with low birthweight although 
that it was not clear whether birthweight had been adjusted for gestational age in that 
study (164, 167).  Another study reported an increased risk of having children small 
for gestational age in female survivors previously treated with abdominal irradiation. 
However, they compared pregnancy outcome in survivors treated with abdominal 
radiotherapy to those treated without abdominal radiotherapy, without comparison 
to offspring of healthy controls (164, 171). In our study, low birthweight seems to 
be attributable to preterm birth. Nevertheless, the majority of these children had a 
birthweight lower than the 50th percentile of offspring of healthy women. Hence, these 
findings will need to be confirmed in a larger cohort and should be compared with a 
large cohort of age-matched healthy controls.
Based on our results, health care-providers should be aware of the increased 
frequency of possible complications during delivery and the post-partum period in 
survivors treated with abdominal radiotherapy during childhood. Therefore, perinatal 
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care should be optimized, specifically in female childhood cancer survivors who 
received abdominal radiotherapy. Consequently, home birth should be discouraged in 
this particular group of childhood cancer survivors.
In conclusion, in our whole cohort of survivors, pregnancy outcome was similar to 
that in healthy controls. As described in earlier studies, women treated with abdominal 
radiotherapy delivered preterm. In addition, we were the first to describe an increased 
frequency of post-partum haemorrhage in female childhood cancer survivors irradiated 
to the abdomen, which stresses the importance of delivery in an inpatient setting in 
these women.
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Controls
(n = 9.031)
‘ALL/NHL’ group
(n = 17/40)
CCS treated with 
chemotherapy only  
(n =21/40)
Highest diastolic tension (mmHg) 81.4 (11.7) 81.5 (12.7) 84.7 (14.1)
Preeclampsia
No
Yes
8.991 (98.9%)
40
17 (100%)
0
21 (100%)
0
Delivery
Vaginal: spontaneous 
 Vaginal: assisted delivery 
secondary caesarean section
Missing
4.928 (54.9%)
2.746 (30.6%)
1.296 (14.4%)
61
6 (46.2%)
5 (38.5%)
2 (15.4%)
4
9 (60.0%)
4 (26.6%)
2 (13.3%)
6
Gestational age (weeks) 39.2 (3.0) 40.3 (1.3) 39.8 (1.3)
Birth weight (grams) 3.271 (714) 3.493 (516) 3.382 (509)
Apgar score 
<8
8
9
10
Missing
458 (5.1%)
526 (5.8%)
2.165 (24.0%)
5.856 (65.0%)
26
0
2 (11.6%)
3 (17.7%)
12 (70.6%)
0
0
0
6 (28.5%)
15 (71.4%)
0
Congenital malformations
No
Yes
Missing
8.834 (98.4%)
145 (1.6%)
52
13 (100%)
0
4
13 (100%)
0
8
Gender 
Male 
Female
unknown
4.727 (52.4%)
4.301 (47.6%)
3
8 (47.1%)
9 (52.8%)
0
11 (52.4%)
10 (47.6%)
0
Postpartum hemorrhage
No
Yes
missing
8.232 (94.8%)
449 (5.2%)
350
12 (100%)
0
0
20 (95.2%)
1 (4.8%)
0
Manual removal of the placenta
No
Yes
Missing 
8.430 (97.1%)
251 (2.9%)
350
12 (100%)
0
0
21 (100%)
0
0
Supplementary table 3.3.3 Parameters in controls, the childhood cancer survivors with ALL 
or NHL and childhood cancer survivors treated with chemotherapy only. Data are presented as 
number (n [%)] or mean (SD). CCS = childhood cancer survivors; ALL – acute lymphoblastic 
leukemia; NHL = non-Hodgkin lymphoma.
66
4anti-müllerian Hormone as marKer 
of oVarian dYsfunCtion

4.1
tHe role of anti-müllerian 
Hormone in tHe ClassifiCation of 
anoVulation and tHe diaGnosis of 
polYCYstiC oVarY sYndrome 
sharon lie fong, izaäk schipper, olivier Valkenburg, 
frank H. de Jong, Jenny a. Visser, Joop s.e. laven
in preparation

4.2
serum anti-müllerian Hormone and inHibin 
b ConCentrations are not useful prediCtors 
of oVarian response durinG oVulation 
induCtion treatment WitH reCombinant 
folliCle stimulatinG Hormone in Women WitH 
polYCYstiC oVarY sYndrome
sharon lie fong,  izaäk schipper, frank H. de Jong, 
axel p.n. themmen, Jenny a. Visser,  Joop s.e. laven
fertil steril. 2011 aug;96(2):459-63
abstraCt 
Objective: To describe changes of anti-Müllerian hormone (AMH) and inhibin B 
during low-dose gonadotrophin ovulation induction (OI) treatment in women with 
polycystic ovary syndrome (PCOS), and thus disturbed selection of the dominant 
follicle. 
Design: observational study . 
Setting: A referral fertility clinic. 
Patients: PCOS women (n=48) and normo-ovulatory women (n=23)
Intervention and main outcome measures: Serum AMH, inhibin B, follicle stimulating 
hormone and oestradiol concentrations were measured at start of stimulation, on the 
day of follicle selection, and at administration of human chorionic gonadotrophin 
during OI cycles and were compared with concentrations measured during the normal 
menstrual cycle. 
Results: Development of a single dominant follicle was observed in 92% of all OI cycles, 
reflected by similar oestradiol concentrations compared with those in spontaneous 
cycles. AMH concentrations were constant during low dose ovarian stimulation. 
Inhibin B concentrations remained elevated in PCOS patients, suggesting prolonged 
survival of small antral follicles, whereas in controls inhibin B concentrations declined 
during the late follicular phase.  
Conclusions: The lack of change in AMH and inhibin B suggest that follicle dynamics 
during low dose stimulation seem different from those during controlled ovarian 
hyperstimulation. In addition, constant AMH and inhibin B suggest that neither AMH 
nor inhibin B is an accurate marker of ovarian response after low dose gonadotrophin 
OI in PCOS patients.
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introduCtion
Chronic anovulation is a major cause of subfertility (31). The great majority of chronic 
anovulatory patients (80%) presents with serum follicle stimulating hormone (FSH) and 
oestradiol concentrations within the normal range and are classified as World Health 
Organization class II for anovulatory infertility (WHO II) (211). Typically, a considerable 
proportion of these women also suffers from polycystic ovary syndrome (PCOS) (33). 
This syndrome is defined by the presence of at least two of three Rotterdam consensus 
criteria: anovulation, hyperandrogenism and/or polycystic ovaries (PCO) (212). 
Although the aetiology of PCOS still remains unclear, this syndrome is characterized by 
failure in dominant follicle selection (48). The selection of antral follicles is disturbed and 
follicles accumulate, resulting in anovulation and PCO (48, 185). 
Fertility treatment in women with WHO II anovulation aims at restoring ovulation, 
by inducing maturation and ovulation of a single dominant follicle (185). If first line 
treatment with clomifene citrate does not result in ovulation or pregnancy, second-line 
treatment consisting of exogenous gonadotrophins is adopted (213). In women with 
PCOS, the increased follicle number may facilitate multifollicular growth during low-
dose stimulation and so these women may be at risk of multiple pregnancies (93). In 
addition, inhibin B and AMH are considered as accurate predictors of ovarian response 
during ovarian stimulation cycles for in vitro fertilization (70, 81). However, results are 
inconclusive regarding the prediction of ovarian response upon stimulation with low 
dose recombinant follicle stimulating hormone (recFSH) (214, 215). 
The aim of this study was to compare changes in serum AMH, inhibin B, FSH and 
oestradiol concentrations in PCOS women during low-dose ovarian stimulation with 
those during normal menstrual cycles in healthy regularly cycling women, in order 
to gain insight in follicle dynamics in PCOS women during low-dose gonadotrophin 
ovarian stimulation. 
materials and metHods
subjects
This study was approved by the local medical ethics review board. Written informed 
consent was obtained from each participant.
General patients’ characteristics and phenotypical characteristics to diagnose 
PCOS were obtained at initial clinical workup, as described earlier (50). Briefly, 
clinical, biochemical and sonographic screening was performed, including history 
taking, anthropometric measurements, pelvic ultra-sonography, and endocrine 
measurements. The median age of PCOS women was 28.7 years (range 23.8 – 39.9 
years). The median body mass index (BMI) was at the upper limit of normal (median 
25.1 kg/m2; range 16.6 – 38.9 kg/m2). Most women suffered from primary infertility 
(63%; n = 30/48) and at start of OI treatment, the median duration of infertility was 2.8 
years (range 0.5 – 17.5 years) (Table 4.2.1). 
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Inclusion criteria for the current study were:  a diagnosis of PCOS according to 
the Rotterdam consensus criteria, with the wish to conceive and ovulation induction 
(OI) treatment with recFSH (Gonal-F® [follitropine α], Merck-Serono B.V., the 
Netherlands) between July 2006 and August 2009. Hyperandrogenism was defined 
as free androgen index (FAI) >4.5 (calculated using the formula [serum testosterone 
concentrations (nmol/L) x 100]/serum sex binding globulin hormone concentrations 
(nmol/L)), testosterone concentrations >3.5 nmol/L and/or serum androstenedione 
concentrations >15.0 nmol/L. Polycystic ovaries (PCO) were defined as 12 or more 
follicles between 2-9 mm diameter (216). 
Normo-ovulatory subjects had participated in an earlier study (4). They had regular 
menstrual cycles and did not use any hormonal treatment or oral contraceptive pills. In 
addition, they had not received treatment for infertility. At inclusion in the earlier study, 
the median age was 27.5 years (range 20.0 – 33.0 years) and the BMI ranged between 
19 and 25 kg/m2. Natural menstrual cycles were monitored with daily blood sampling 
and pelvic ultra-sonography, starting 10 to 12 days after a positive urinary LH test 
during a first cycle until normal ovulation in the next cycle. The latter was confirmed 
sonographically and 7 days later by measuring serum progesterone concentrations (4). 
For the current study, only data from the natural follicular phase were included. 
treatment protocol 
Ovulation induction treatment was started on the third to fifth day after spontaneous 
menstrual bleeding or after progestagen-induced bleeding. Treatment protocols and 
assessment of ovarian response have been described previously (93). In summary: the 
first treatment cycle was started with daily subcutaneous injection of 37.5 IU recFSH. 
If ovarian response was present upon the starting dose during the first cycle, a second 
cycle was performed using the same fixed dose protocol. If not, the second treatment 
Characteristic Women with PCOS Normo-ovulatory women 
Number (n) 48 23
Age (years) (median, range) 28.7 (23.8 – 39.9)* 27.5 (20.0 – 30.0)
Menstrual cycle (n)
Regular
Oligomenorrhoea
amenorrhoea
0
27
21
23
0
0
Fertility (n)
Spontaneous pregnancy
Primary subfertility
Secundary subfertility
0
30
18
14/23
0
0
Total follicle count in both ovaries  
(mean, range) 
22 (4.5 – 51) 11 (4 – 21)
Hyperandrogenism (n) 27 0
Table 4.2.1. General patients’ characteristics in women with polycystic ovary syndrome (PCOS) 
and normo-ovulatory women (*: P = 0.09).  
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cycle was started at a dose 37.5 IU/day above the response dose during the first cycle, 
according to the step-down regimen. Then, the recFSH dose was decreased, with 37.5 
IU/day during 3 days in case of response (217). Human chorionic gonadotrophin (hCG; 
[Pregnyl®; Schering-Plough, The Netherlands]) was administered intramuscularly as a 
single dose of 5000 IU on the day upon which one or two follicles of 18 mm could be 
visualized. The presence of three or more follicles larger than 16 mm was considered as 
hyperresponse and consequently, the cycle was cancelled. OI treatment was continued 
until pregnancy was achieved, with a maximum of six cycles.
endocrine measurements
Serum was drawn on three sequential time points for assessment of AMH, inhibin B, 
FSH and oestradiol. In study subjects, samples were drawn at the start of exogenous 
FSH administration (T1), at selection of the dominant follicle (T2) and on the day of 
hCG administration, at the end of ovarian stimulation (T3). The day of selection of the 
dominant follicle was defined as the day on which a follicle reached a diameter of 10 
mm or larger and enlargement of this follicle during subsequent days until ovulation. 
In normo-ovulatory women, samples were drawn on cycle day 3, 4 or 5, on the day of 
follicle selection and on the day prior to the LH surge and were used for comparison 
with samples from study subjects. Samples were stored at -20 ˚C until assessment of 
AMH. Inhibin B, FSH and oestradiol were measured on the same day of withdrawal. 
Serum AMH concentrations were measured with an in-house double-antibody 
enzyme-linked immunosorbent assay (79). The assay is available through DSL Inc. 
(DSL-10-14400; Diagnostic Systems Laboratories Inc. Webster, TX, USA) (79). Serum 
inhibin B concentrations were determined using an enzyme-linked immunoassay 
(Oxford Bio Innovation, Oxford, UK).  Luminescence-based immunoassays were used 
to measure FSH concentrations (Immulite, Siemens DPC, Los Angeles, CA, USA). A 
coated tube radioimmunoassay was used to assess oestradiol serum concentrations 
(Siemens DPC). Intra- and interassay coefficients of variance were <10 and <5% 
for AMH, <9 and 15% for inhibin B, <3 and 8% for FSH, <5 and 7% for oestradiol, 
respectively. 
data analysis
General characteristics of eligible patients and normo-ovulatory women were compared 
using non-parametric tests, because of skewed distribution of the data (not shown) 
and limited sample size. ANOVA for repeated measurements was used to compare the 
effect of time on endocrine parameters in PCOS women and normo-ovulatory women 
and to compare changes in endocrine parameters between PCOS women and normo-
ovulatory women, followed by an independent samples t-test in case of the presence of 
significant differences. Data are presented as medians with ranges. AMH and oestradiol 
concentrations were logarithmically transformed to achieve normal distribution. 
Serum AMH concentrations are presented in µg/L (1 µg/L = 7.14 pmol/L). Statistical 
analysis was performed using Statistical Package for Social Sciences 15.0 (SPSS Inc., 
Chicago, IL, USA). A P  value of <0.05 indicates statistical significance. 
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results
subjects’ characteristics 
In accordance with the inclusion criteria, 48 women with PCOS were eligible for 
analysis. All 48 women had irregular cycles. All but 2 women had PCO and 27 women 
(27/48; 56%) were hyperandrogenic (Table 4.2.1). The median age in PCOS women was 
not significantly different from that in 23 normo-ovulatory women (median 27.5 years, 
range 20.0 – 33.0 years) (P = 0.09). Fourteen of the 23 normo-ovulatory women had 
been pregnant previously (4).
Characteristics of ovarian stimulation 
One treatment cycle per woman was included. In 18 patients, the first day on which 
the dominant follicle was observed, coincided with the day on which hCG was 
administered. Consequently, in these patients serum was drawn on only two occasions. 
In the remaining 30 patients, serum sampling was performed on 3 independent days. In 
5 patients OI cycles were cancelled: in 3 patients, at least 2 follicles larger than 16 mm 
were observed at hCG administration, which indicated hyperresponse and an increased 
risk of multiple pregnancy. In another patient, surplus follicles were punctured prior 
to hCG administration and finally, in one patient a postovulatory follicle was observed 
during monitoring of ovarian response, indicative for premature LH surge. In 42 of the 
43 ongoing OI cycles, monofollicular growth was observed, whereas one ongoing cycle 
had resulted in 2 follicles of 16 mm. The median duration of stimulation was 15 days 
(range 5 – 38 days). Eventually, analysis was performed  in 43 women with ongoing OI 
cycles. 
endocrine parameters
Serum AMH concentrations remained constant during FSH-stimulated cycles and 
normal cycles (P = 0.136), although AMH concentrations in PCOS women were 
significantly higher than in normo-ovulatory women (P = 0.007) (Figure 4.2.1). Indeed, 
post-hoc analysis showed that at all time points PCOS women had higher serum AMH 
concentrations than normo-ovulatory women (P = 0.004 at start; P = 0.003 at selection; 
P = 0.02 at end of stimulation) (Table 4.2.2).
Inhibin B concentrations within OI or natural cycles did not change significantly 
over time (P = 0.343). However, the repeated measures analysis revealed that there was 
a significant interaction between time and group (P = 0.039), suggesting that there is a 
change in inhibin B concentrations during OI and natural cycles and that this change 
differs between both groups. In OI cycles inhibin B concentrations remained relatively 
constant, whereas in natural cycles inhibin B concentrations increased from T1 to T2 
and declined from T2 to T3. As a consequence, inhibin B concentrations were nearly 
twice as high in PCOS women at the end of an OI cycle than in normo-ovulatory 
women on the day prior to the LH surge (P < 0.0001) (Table 4.2.2) (Figure 4.2.1). 
FSH concentrations were significantly different between PCOS and normo-
ovulatory women (P < 0.0001). At all time points FSH concentrations were higher in 
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PCOS women compared with normo-ovulatory women (P < 0.0001 at T1 and T2; P 
= 0.01 at T3) (Table 4.2.2) (Figure 4.2.1). However, concentrations remained constant 
during both OI and natural cycles (P = 0.557) (Figure 3.2.1). 
Oestradiol concentrations changed significantly within OI cycles and natural cycles 
(P = 0.032), however the change over time was similar in both groups (P = 0.396). 
Both cycles showed an increase in oestradiol concentrations at T3 (Figure 4.2.1). 
Overall, oestradiol concentrations  in OI cycles were not significantly different from 
concentrations in natural cycles (P = 0.883) 
disCussion 
To our knowledge, our study is the first to describe the dynamics of AMH, inhibin 
B, FSH and oestradiol concentrations during low-dose FSH ovarian stimulation in 
normogonadotropic anovulatory women. This treatment regimen has been shown to 
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Fi ure 4.2.1. Changes in median serum anti-Müllerian hormone (AMH), inhibin B, follicle 
stimulating hormone (FSH) and oestradiol (E2) (and ranges) concentrations in PCOS patients 
during ovulation induction cycles (filled dots and solid lines) and in normo-ovulatory controls 
during normal menstrual cycles (open squares and dashed lines) at start of ovarian stimulation 
(T1), at selection of the dominant follicle (T2) and at the end of stimulation (T3). 
* P <0.05: significant change over time, which was different between PCOS and normo-ovulatory 
women
# P <0.05: significant change over time, which was similar in both PCOS and normo-ovulatory 
women
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be successful and cost-effective in several studies (185, 218, 219). In the present study 
mono-ovulation was achieved in the majority of women with PCOS, as confirmed 
by the development of a single dominant follicle and a similar pattern and degree of 
increasing oestradiol concentrations in both OI cycles and spontaneous cycles. 
Serum AMH concentrations were constant in both women with PCOS and normo-
ovulatory women, in accordance with previous studies (128, 220). This is in contrast 
with the decline in serum AMH concentrations observed during controlled ovarian 
hyperstimulation for in vitro fertilization (147, 221). It has been suggested that the 
decline in AMH concentrations reflects the shift of AMH-producing, small antral 
follicles to the subsequent stage upon supraphysiological doses of recFSH, since AMH 
expression gradually decreases in antral follicles sized 6 mm and larger (73). The 
constant AMH concentrations in PCOS women suggest, however, that upon low-dose 
recFSH stimulation, the cohort of small antral follicles was not significantly reduced, 
despite the presence of an increased number of follicles, reflected by high serum AMH 
concentrations at start of stimulation.  Thus, ovarian stimulation with low-dose recFSH 
mimics a physiological cycle, as reflected by mono-ovulation in most PCOS women. 
In contrast with AMH concentrations, inhibin B concentrations did show different 
dynamics between PCOS and control women. At the end of low-dose ovarian 
stimulation, inhibin B concentrations remained elevated, whereas in natural cycles, 
inhibin B declined. This prolonged elevation of inhibin B concentrations has been 
described previously (222) and would be suggestive of sustained multiple follicular 
development during the late follicular phase. In spontaneous cycles, multiple antral 
T1 P T2 P T3 P
AMH (µg/L) 0.004 0.003 0.02
PCOS 13.6 (3.4 – 56.4) 14.6 (2.1 – 37.7) 13.4 (2.8 – 42.9)
controls 8.8 (2.1 – 27.8) 8.5 (1.8 – 25.8) 9.2 (2.0 – 30.8)
Inhibin B (ng/L) 0.15 0.98 <0.001
PCOS 102 (9 – 212) 141 (67 – 2,554) 166 (39 – 4,757)
controls 68 (11 – 164) 146 (48 – 310) 79 (31 – 131)
FSH (IU/L) <0.001 <0.001 0.01
PCOS 6.6 (0.1 – 11.9) 7.2 (4.3 – 19.1) 7.1 (3.7 – 15.1)
controls 4.6 (3.1 – 7.7) 5.3 (3.1 – 7.3) 5.2 (2.6 – 10.2)
oestradiol (pmol/L) - - -
PCOS 139 (57 – 387) 283 (93-1,404) 699 (180 – 6,886)
controls 149 (98 – 404) 201 (123 – 432) 788 (387 – 1,600)
Table 4.2.2. Median serum anti-Müllerian hormone (AMH), inhibin B, follicle stimulating hormone 
(FSH) and oestradiol (E2) concentrations (and ranges) in PCOS patients during ovulation induction 
cycles compared with concentrations in normo-ovulatory controls during normal menstrual 
cycles at start of ovarian stimulation (T1), at selection of the dominant follicle (T2) and at the end 
of stimulation (T3). P-values are results of the independent samples t-test, performed following a 
significant difference in the repeated measurement analysis. 
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follicles are recruited by FSH. Because of decreasing FSH concentrations, most of 
them will become atretic, resulting in the development of a single dominant follicle. 
Apparently, upon continuous low-dose FSH administration, the physiological decrease 
in FSH was overruled and the FSH-recruited follicles survived longer during OI cycles, 
explaining the significantly elevated inhibin B concentrations at the end of stimulation 
in our treated subjects. 
Prior to stimulation, FSH concentrations were higher in PCOS women than in normo-
ovulatory women. Since age was similar in PCOS women and normo-ovulatory women, 
these high FSH concentrations may reflect impaired FSH sensitivity in our PCOS cohort. 
Indeed, it is widely considered that selection of the dominant follicle is impaired in women 
with PCOS, due to failure of FSH-dependent follicle recruitment (223). Apparently, by 
administration of a small amount of exogenous FSH, the ‘blocked’ cyclic recruitment in 
PCOS women can be overruled and multiple follicles surpass the FSH threshold (224). 
Despite this prolonged survival of follicles with continuous low-dose FSH administration 
after cyclic recruitment, development of a single dominant follicle was unaffected in the 
majority of treated PCOS subjects, as reflected by mono-ovulation. This implies that upon 
stimulation with low-dose exogenous FSH, multiple antral follicles are present, but they 
seem to be less responsive to FSH and possibly less viable. 
We hypothesized that in the studied population of women with PCOS, several 
treatment cycles would result in hyperresponse to low-dose stimulation. Then, 
multifollicular growth would be expected and AMH concentrations would decrease 
during low-dose stimulation. It might be expected that this decrease is predictive for 
ovarian hyperresponse, and thus cycle cancellation. Ovulation induction cycles were 
cancelled in five patients, of whom four had multiple follicular growth. This may 
indicate that the studied cohort of PCOS women had rather favourable factors of 
successful OI treatment outcome (93). Consequently, in a more obese population with 
a higher follicle number or a higher percentage of more severe hyperandrogenism, 
multifollicular growth might occur more often than in the currently studied subjects. In 
addition, in our study, a starting dose of 37.5 IU recFSH was applied and seemed quite 
efficient and save, with respect to hyperstimulation. Moreover, the low cancellation rate 
may also suggest that follicle growth was well monitored.
In conclusion, serum AMH concentrations were constant during low-dose 
ovulation induction.  Although inhibin B concentrations at the end of stimulation were 
indicative of prolonged survival of antral follicles, mono-ovulation was not affected. 
Unfortunately, in the current study, data on the number of growing antral follicles during 
stimulation was not available. However, the lack of change of serum AMH and inhibin 
B concentrations during low-dose stimulation and mono-follicular development 
in PCOS women seem distinctly different from that during controlled ovarian 
hyperstimulation. This suggests that follicle dynamics during ovulation induction are 
different from that during controlled ovarian stimulation with pharmacological doses 
of recFSH. In addition, neither AMH nor inhibin B seems useful as a marker of ovarian 
response after low-dose ovarian stimulation in women with PCOS.
serum amH during ovulation induction
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abstraCt 
Background: Serum anti-Müllerian hormone (AMH) levels decline with increasing 
age and constitute a sensitive marker for ovarian ageing. In addition, basal serum 
AMH concentrations predict ovarian response during in vitro fertilization (IVF) 
cycles. Concomitantly, oocyte quantity and embryo quality decrease with advancing 
age. Hence, it was hypothesized that AMH in serum constitutes a marker for embryo 
quality. 
Methods: Women aged 37 and younger with regular menstrual cycles, normal body 
mass index and partners with normal semen parameters were randomly assigned 
to either a standard or mild stimulation protocol for IVF treatment. Blood samples 
were drawn at cycle day 3 and at the day of hCG administration. Embryo quality was 
assessed using embryo morphology score and preimplantation genetic screening. 
Results: Serum AMH levels on cycle day 3 were correlated with the number of 
oocytes retrieved in both groups. AMH and embryo morphology were correlated 
after mild stimulation, but not after conventional ovarian stimulation. AMH and the 
chromosomal competence of embryos were not correlated. 
Conclusions: Serum AMH is predictive for ovarian response to stimulation. However, 
the lack of a consistent correlation with embryo morphology and embryo aneuploidy 
rate is not in favour of a direct relationship between oocyte quantity and embryo 
quality. 
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introduCtion
Anti-Müllerian Hormone (AMH) is a dimeric glycoprotein and member of the 
transforming growth factor-β superfamily (225). Members of this family play a role 
in follicle maturation and development. In rodent studies, accelerated depletion of 
the primordial follicle pool was observed in AMH knock-out (AMH-KO) mice. In 
addition, follicles in AMH-KO mice were more sensitive to follicle stimulating hormone 
(FSH). Despite the presence of low serum FSH concentrations, a higher number of 
small growing follicles was observed in AMH-KO mice as compared with wild-type 
mice (67). AMH is expressed in ovarian granulosa cells,  especially in granulosa cells 
of those follicles at the stages of follicular development between initial recruitment and 
cyclic recruitment by FSH, i.e. preantral and small antral follicles. Hence, AMH seems 
to be an important regulator at two crucial points in folliculogenesis, i.e. initial follicle 
recruitment and cyclic selection for dominance (125). 
In the human ovary, AMH is expressed in granulosa cells of secondary, preantral 
and small antral follicles ≤ 4 mm in diameter and expression is absent in follicles 
> 8 mm (73). This expression pattern in small growing follicles is similar to that in 
mice, suggesting a similar role for AMH in humans. Consequently, serum AMH 
concentrations correlate well with the number of antral follicles. Indeed, the decline 
of antral follicles with age is reflected by a decline in serum AMH levels (70, 80, 84). 
In addition, different reports have demonstrated that serum AMH levels correlate with 
outcome of ovarian hyperstimulation. Poor response in in-vitro fertilization (IVF), 
indicative of a diminished ovarian reserve, is associated with reduced baseline serum 
AMH concentrations (63, 70, 96, 226, 227). Therefore, AMH serum levels constitute a 
sensitive marker of ovarian reserve. 
With increasing age, the primordial follicle pool diminishes, resulting in a decrease in 
oocyte quantity. At the same time, the incidence of numeric chromosomal abnormalities 
is increased in oocytes obtained after ovarian stimulation in women older than 37 years 
(28). This suggests that with increasing age, a concomitant decrease in oocyte quantity 
as well as quality is observed. In assisted reproductive techniques, the best embryos are 
selected for transfer. Until now, these embryos are selected based on rather subjective 
criteria, according to a widely used morphology score (228). While embryos rated as 
high quality by this morphological assessment are associated with higher implantation 
and pregnancy rates, successful implantation and ongoing pregnancy cannot be 
predicted with certainty. In addition, over 50% of the embryos transferred appears to 
be chromosomally abnormal (229, 230). In this study, embryo quality was assessed 
by performing preimplantation genetic screening (PGS) for numeric chromosomal 
abnormalities as well as by traditional embryo morphology score. 
AMH has previously been shown to be a better predictor of ovarian reserve than 
age (96). Since oocyte quantity as well as oocyte quality affect embryo quality and seem 
to be associated with ageing, it was hypothesized that AMH might also correlate with 
embryo quality. Accordingly, in patients receiving IVF treatment cycles, AMH might 
predict their response to ovarian stimulation as well as their chances of conceiving. 
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The aim of this study was to determine the correlation between serum AMH levels and 
embryo quality, employing PGS. 
materials and metHods
subjects
This study was approved by the local medical ethics review board of the participating 
hospitals and by the Dutch Central Committee on research involving human subjects 
(CCMO). Written informed consent was obtained from all participants. Patients 
participated in a randomized controlled trial (RCT), during one IVF treatment cycle, 
as described earlier (229). 
study design 
Patients were randomly assigned to a conventional treatment group (group 1) or to a 
mild stimulation group (group 2) as described previously (229, 231). Embryo score was 
defined as the mean score of all embryos obtained per patient, rated on the third day 
after oocyte retrieval.  Preimplantation genetic screening was performed on embryos 
with more than five blastomeres. Two cells were removed by biopsy, unless the embryo 
consisted of only six blastomeres. Fluorescent in-situ hybridization (FISH) analysis was 
performed to determine the copy number of nine pairs of chromosomes (1, 7, 13, 15, 
16, 18, 21, 22, X and Y) (232). Embryos were classified as either euploid or aneuploid 
according to FISH results obtained from the first biopsied blastomere. 
In both groups, baseline blood samples were obtained on cycle day 3, before ovarian 
stimulation was started. Subsequently, on the day of human chorionic gonadotrophin 
(hCG) administration, a second blood sample was obtained. Serum samples were stored 
at -20°C and assayed for AMH, luteinizing hormone (LH), follicle stimulating hormone 
(FSH) and inhibin B. AMH levels were assayed using an in-house double-antibody 
enzyme-linked immunosorbent assay (ELISA) kit, with intra- and interassay coefficient of 
variation of <5% and <10%, respectively (79). Serum levels of LH and FSH were measured 
using luminescence based immunoassays (Immulite 2000, Diagnostic Products Corp., 
Los Angeles, CA, USA). Intra- and interassay coefficients of variation were less than 4% 
and 7% for LH and less than 3% and 6% for FSH, respectively. Dimeric inhibin B levels 
were assessed using an immunoenzymometric assay obtained from Serotec (Oxford, 
UK). Intra- and interassay coefficients of variance were less than 7% and 14% respectively. 
data analysis
Data obtained from the blood samples drawn on the day of hCG administration 
were used to calculate the change in serum AMH concentrations during ovarian 
stimulation: [AMH on the day of hCG administration] – [AMH before start of ovarian 
stimulation]. Primary outcome measures were serum AMH concentrations before and 
after standard or mild ovarian stimulation, embryo morphology assessed by embryo 
morphology score and aneuploidy rate assessed by PGS. 
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Non-parametric Mann-Whitney-U and Chi square tests were used to compare 
data in patient subgroups. Correlations between data were assessed using Pearson or 
Spearman correlation tests and were expressed as correlation coefficient r. Correlations 
between AMH on the day of hCG administration and outcome parameters were 
assessed by analysis of covariance (ANCOVA), after adjustment for baseline AMH 
values. A P value < 0.05 was considered to be statistically significant. Statistical analysis 
was performed using a commercially available software package (SPSS, SPSS Inc., 
Chicago, IL, USA). 
results 
In the present study, 125 patients were included, of whom 51 (40.8%) were assigned 
to the standard protocol (group 1) and 74 (59.2%) to the mild protocol (group 2). On 
average, participants were 33.2 (range 22.5 – 37.9) years old and their body mass index 
(BMI) was 22.7 (range 18.1 – 30.5) kg/m2. No differences were observed in demographic 
patient characteristics between the two groups. Patients in group 1 were stimulated 
significantly longer as compared with patients in group 2 (median 11 and 9 days, 
respectively) (P < 0.001). Figure 4.3.1 shows details concerning patients who withdrew 
or were excluded from analysis, as described earlier (229). In the additional patients 
included in the present study, two patients withdrew prior to ovarian stimulation, 
two further patients were excluded due to ovarian hyperstimulation syndrome and in 
another two, fertilization failed after standard ovarian stimulation. Furthermore, another 
patient dropped out because of a spontaneous pregnancy, one more cycle was cancelled 
due to low response and in 18 patients embryos were not available for analysis after 
mild stimulation. Eventually, in 33% of the patients assigned to group 1 (conventional 
ovarian stimulation), embryos were not suited for transfer. Of the patients in group 2 
(mild ovarian stimulation), 42% underwent embryo transfer after biopsy for PGS.  
Serum AMH levels before the start of IVF cycle were comparable in both groups 
(P = 0.71) (Figure 4.3.2). During stimulation in group 1, AMH levels decreased 
significantly (P = 0.002). In group 2, baseline AMH levels and AMH levels on the 
day of hCG administration were not different (P = 0.193) (Figure 4.3.2). Serum AMH 
concentrations on the day of hCG administration were significantly lower in group 1 
as compared with group 2 (P < 0.001). This difference remained statistically significant 
after adjustment for the number of oocytes retrieved and basal AMH concentrations 
(P < 0.001). As described in the previous study, more oocytes were retrieved in group 
1 as compared with group 2 (P = 0.001). In addition, more fertilized oocytes were 
obtained in group 1 (P = 0.014). However, fertilization rate (P = 0.227) and the number 
of ongoing pregnancies (P = 0.842) were comparable in both groups (229). 
In group 1, serum AMH concentrations on cycle day 3 and the number of oocytes 
retrieved were positively correlated (r = + 0.47; P = 0.002) (Figure 4.3.3A). However, 
baseline serum AMH levels were not correlated with the number of fertilized oocytes 
(r = + 0.17; P = 0.29), nor with fertilization rate (r = - 0.21; P = 0.21). In addition, no 
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IVF
n = 46 (90%)
Embryo 
transfer
n = 77 (62)%
Preimplantation genetic 
screening (PGS) 
n = 43 (58%)
Preimplantation genetic 
screening (PGS)
n = 34 (67%)
Oocyte retrieval
n = 61 (82%)
Oocyte retrieval
n = 43 (84%)
IVF
n = 69 (93%)
conventional stimulation protocol: 
225 IU/d recFSH GnRH agonist 
n = 51 (40,8%)
mild stimulation protocol: 
150 IU/d recFSH GnRH antagonist
n = 74 (59,2%)
Randomisation
n = 125
5 (10%) drop-out 
1 spontaneous 
pregnancy
4 non-medical reasons
5 (7%) drop-out
3 spontaneous pregnancies
2 non-medical reasons
3 (6%) cancelled 
3 OHSS
8 (11%) cancelled 
8 low response
9 (18%) no embryos for screening
  
5 no fertilisation 
4 embryos not suitable 
for analysis
18 (16%) no embryos for screening
7 no fertilisation
11 embryos not suitable for 
analysis
Figure 4.3.1  
Figure 4.3.1. Flow diagram of patients through phases of trial. 
correlation was observed with embryo morphology, defined by morphology score as 
well as with aneuploidy rate (r = -0.15, P = 0.37; r = + 0.05, P = 0.77, respectively) (Figure 
4.3.3B). The decrease in AMH concentrations during standard ovarian stimulation 
was not correlated with the number of oocytes retrieved, fertilization rate, embryo 
morphology or aneuploidy rate (r = + 0.25, P = 0.14; r = + 0.22, P = 0.20; r = - 0.24, P 
= 0.15; r = - 0.03, P = 0.88, respectively).   
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In group 2, baseline serum AMH concentrations were positively correlated with 
the number of oocytes (r = + 0.29; P = 0.03) and with the embryo score on day of 
embryo biopsy expressed by morphology score (r = + 0.41; P = 0.005) (Figure 4.3.3A 
and 4.3.3B). However, no correlation was found between baseline AMH and number 
of fertilized oocytes or fertilization rate, nor between AMH and results of aneuploidy 
screening (r = - 0.05, P = 0.74; r = + 0.22, P = 0.12; r = - 0.10, P = 0.54, respectively). The 
decrease in serum AMH concentrations during mild stimulation was correlated with 
the number of oocytes retrieved (r = + 0.34, P = 0.016). No correlation was observed 
with morphology score, aneuploidy rate or fertilization rate (r = 0.17, P = 0.25; r = 
-0.03, P = 0.88; r = -0.26, P = 0.07 respectively). 
In both stimulation protocol groups, serum AMH concentrations on the day of 
hCG administration were positively correlated with the number of oocytes (P = 0.023). 
No correlations were observed with embryo quality expressed by embryo score or 
aneuploidy rate, nor with fertilization rate. 
disCussion
Ongoing pregnancy and live birth are the most important endpoints in assisted 
reproductive treatment. These outcome measures are mainly affected by embryo 
quality and hence, oocyte quality. Therefore, in the current study embryo morphology 
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Figure 4.3.2. Box Whisker-plot of serum AMH levels in standard stimulation group versus mild 
stimulation group. 
Serum AMH levels in patients in standard versus mild stimulation group at the start of stimulation 
cycle (hatched boxes) and on the day of hCG administration (open boxes). A statistically 
significant decrease in serum AMH levels was only observed in the standard protocol group 
(a: P = 0.002). A statistically significant difference between serum AMH levels at day of hCG 
administration  was observed between the groups (b: P < 0.001).
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score as well as aneuploidy rate were used to assess embryo quality. Recently, a positive 
correlation was observed between the number of oocytes retrieved and the percentage 
abnormal embryos after mild stimulation (229). In the current study, AMH at start of 
stimulation was correlated with the number of oocytes after mild as well as standard 
stimulation and therefore, similar findings to the previously mentioned study were 
expected. Indeed, the current results showed a negative correlation between the 
number of oocytes retrieved and the percentage of normal oocytes (data not shown). 
Apparently, among the few oocytes retrieved after mild stimulation, the majority must 
have been chromosomally normal. However, the lack of correlation between AMH in 
serum and aneuploidy rate suggests that AMH cannot be used as a marker for the rate 
or incidence of aneuploidy.
After standard stimulation, AMH serum levels decreased significantly. This decrease 
in AMH levels between start of stimulation and the day of hCG administration reflects 
the decline of the cohort of small growing follicles recruited during ovarian stimulation 
(221, 226). Studies in mice revealed that the FSH sensitivity of follicles is reduced by 
AMH (67, 68). Therefore, it might be hypothesized that in women, in the presence 
of low serum AMH levels, FSH sensitivity is increased, and consequently the most 
FSH-sensitive follicles will be recruited. Because in the present study, basal serum 
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Figure 4.3.3. Scatter plots of baseline AMH serum levels (logarithmically transformed) and 
Number of oocytes retrieved at oocyte pick. Pearson’s correlation coefficient r  = 0,47 (P = 0,002) 
in the standard (dotted line and open boxes) and r = 0,29 (P = 0,03) in the mild stimulation 
group (solid line and filled boxes). 
Mean embryo score per number of rated embryos; lowest score represents best embryo 
morphology. Pearson’s correlation coefficient r = -0,15 (P = 0,37) in the standard (dotted line and 
open boxes) and r = 0,41 (P = 0,005) in the mild stimulation group (solid line and filled boxes). 
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AMH levels were comparable between the two stimulation protocols, the difference 
in the number of oocytes retrieved was solely dependent on the stimulation regimen. 
For this reason, more follicles were recruited during conventional stimulation, due 
to an extended window of recombinant FSH availability. On the other hand, during 
mild stimulation, only the most FSH-sensitive follicles were recruited, due to their 
decreased FSH sensitivity. Consequently, AMH serum concentrations during mild 
stimulation were correlated with the number of follicles as well as with embryo 
morphology. Since pregnancy rates were similar between the two protocols, oocyte 
quality in the mild stimulation group must have been better. In contrast, during 
conventional stimulation the recruited cohort consisted of a mixed population 
of follicles with different individual FSH sensitivities and consequently different 
developmental stages, harbouring apparently good quality and poor quality oocytes. 
Indeed, in such a protocol the correlation between basal serum AMH levels and follicle 
number was still present. However, the correlation between AMH and embryo quality 
was lost, as is apparent from the current study. Similar findings have been reported 
in two recent studies (130, 231). In patients undergoing IVF, AMH levels on the day 
of hCG administration exceeding a predefined threshold were positively correlated 
with embryo quality, higher implantation rates and higher ongoing pregnancy rates 
as compared with patients with serum AMH concentrations below this threshold 
value (149). Higher AMH concentrations on the day of hCG administration may have 
resulted from more physiological ovarian stimulation protocols, during which lower 
numbers of oocytes are recruited. It may be assumed, that during the physiological 
process of single follicle selection, the one follicle containing the best oocyte will 
ovulate. Hence, it seems that the mild stimulation protocol mimics the physiological 
situation more closely. Although it induces less pre-ovulatory oocytes, they constitute 
the better quality oocytes since implantation rates were higher, explaining the similar 
pregnancy rates observed in this study.  
AMH levels in follicular fluid might be indicative for oocyte quality. Recently, 
it has been reported that intra-follicular AMH concentrations from patients with 
fertilized oocytes were higher than those from patients with non-fertilized eggs (233). 
In addition, clinical pregnancy rates and embryo implantation rates were significantly 
higher in patients with follicles containing high AMH concentrations (234). Similar to 
the present findings, this almost “physiological“ stimulation protocol resulted in one 
follicle containing a qualitatively good oocyte. However, a negative correlation between 
AMH in serum and patients age or between serum AMH and failure to retrieve oocytes 
was absent. Apparently, differences in follicular fluid AMH concentrations are not 
necessarily reflected in serum AMH concentrations. This might be due to the relatively 
low number of follicles recruited during mild stimulation exhibiting a similar FSH 
sensitivity and therefore containing similar amounts of AMH. Hence, these follicles all 
contribute in an equal proportion to the AMH serum level. In contrast, in a conventional 
stimulation protocol, the recruited follicles exhibit different FSH sensitivities and 
might also contain different levels of AMH. Hence, the correlation between the serum 
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AMH concentration and the number of follicles is lost after conventional ovarian 
stimulation. Indeed, in the present study AMH serum levels were only positively 
correlated with embryo morphology in the mild stimulation protocol. This might also 
be an explanation why data on correlations between serum AMH concentrations and 
implantation or pregnancy rates are contradictory (63, 149, 226, 235, 236). 
In conclusion, baseline serum AMH concentrations are well correlated with ovarian 
response during conventional as well as during mild ovarian stimulation. Although 
serum AMH levels were correlated with embryo morphology scores in the mild 
stimulation group, a similar correlation could not be demonstrated in the conventional 
stimulation protocol. A consistent correlation between serum AMH concentrations 
and embryo quality, as assessed by PGS, was not observed. It seems, therefore, that 
basal serum AMH concentrations are not an adequate marker for embryo quality. 
However, AMH seems to play an important role during folliculogenesis, by modulating 
FSH sensitivity of individual follicles.  The exact role of AMH in the prediction of 
oocyte quality during assisted reproductive treatment remains to be established.
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5General disCussion

Postponement of childbearing has led to increased rates of age-related female 
infertility. In clinical practice, those women with reduced reproductive capacity need 
to be identified in order to counsel them on their chances of pregnancy. Consequently, 
increased attention has been given to the identification of markers of ovarian reserve. 
Serum anti-Müllerian hormone (AMH) levels have been described as an accurate 
marker of ovarian reserve. AMH is expressed  in granulosa cells of primary follicles 
and continues until the early antral stage during which expression is strongest (73). 
Many clinical studies have confirmed that serum AMH concentrations correlate well 
with the antral follicle count (AFC) (51, 80, 85, 96). Consequently, AMH levels not 
only constitute a direct marker of the AFC but also seem to indirectly reflect the size of 
the primordial follicle pool (80). In addition, serum AMH has also been described as 
a marker of polycystic ovary syndrome (PCOS), since it reflects the excessive number 
of antral follicles (51, 85). Hence, serum AMH levels seem to constitute a promising 
marker of ovarian reserve and ovarian dysfunction. The aim of this thesis was to study 
the value of serum AMH levels as a marker of ovarian reserve and ovarian dysfunction 
in a clinical setting.  
5.1. amH as a marKer of ooCYte quantitY
Ideally, a marker of ovarian reserve should be able to predict the onset of decreased 
fertility and the age of menopause. In addition, such a marker should also be able 
to reliably detect an early decline in ovarian reserve in the individual woman, 
and consequently, these women should be advised to not further postpone their 
childbearing, in order to avoid future assistance in reproduction. Moreover, such an 
ovarian reserve marker requires a clear cut-off value that discriminates individuals 
with normal ovarian reserve from those with diminished ovarian reserve. Until now, 
no clear cut-off levels have been defined for FSH and AFC, the more traditional ovarian 
reserve markers (237, 238). Despite the lack of well-defined normal values of AMH, 
assessment of AMH levels is widely applied in the prediction of ovarian response 
during assisted reproductive techniques (ART) (60, 63, 70, 81, 95, 226, 227, 235, 239-
243). Numerous studies have attempted to define a cut-off level for serum AMH that 
might be predictive of poor ovarian response (148, 149, 235, 242, 244-246). A cut-off 
level that might discriminate women with expected poor response from those with 
normal ovarian response and successful outcome of ART, may also serve as a cut-off 
level of diminished ovarian reserve. However, the discriminative levels that have been 
proposed for serum AMH so far show a considerable variation, that seems to depend 
on the etiology of infertility and age of the study subjects included. Indeed, some 
studies have included infertile women older than 38 years, in whom poor response 
might be expected (242, 244), whereas other studies have measured AMH levels in a 
more random infertile population (148, 149). Furthermore, in some of these studies the 
enzyme-linked immunosorbent assay (Beckman-Coulter) had been used to measure 
AMH levels (148, 149), whereas others used the ultrasensitive immunoassay available 
discussion
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through Diagnostic System Laboratories (DSL) (242, 244). Fortunately, nowadays a 
new assay is available (Gen II Beckman-Coulter assay, Beckman Coulter, Inc., Webster, 
Texas), and its general use would reduce inter-assay variability in future studies. 
Finally, this large variation in AMH serum concentrations in infertile women indicates 
the urgent need to investigate variation of AMH levels in the normal population. In our 
study on normative data in a large cohort of healthy females, cut-off levels of the normal 
values were assessed using the 10th and 90th percentile of normative data (chapter 
2.1). At any age, there was a wide range in AMH levels. A similar range in AMH levels 
has also been described in large cohort studies in healthy girls (99, 247) and regularly 
cycling, but infertile women (100). Furthermore, during early childhood and from 
the age of 25 years onwards, the lower limit of normal values seemed to approximate 
the limit of detection of AMH levels. As a consequence, it will be extremely difficult 
to distinguish women with a compromised ovarian reserve from those with normal 
ovarian reserve based on a single AMH measurement. Furthermore, the large variation 
in AMH levels  in a normal, proven fertile population, indicates that defining a cut-off 
value for poor response with a sufficient predictive power may be difficult. 
Our cross sectional data (chapter 2.1) only provide information on the current status 
of ovarian reserve, but not on the progression towards menopause. Consequently, from 
these data it cannot be concluded whether regularly cycling females with an AMH 
level below the 10th percentile indeed have a diminished ovarian reserve. Although 
two longitudinal cohort studies have suggested that AMH might be predictive of age 
at menopause (83, 248), long term follow-up of ovarian function and reproductive 
status, with frequent serial analysis, is needed in females with normal ovarian 
function to determine whether women younger than 35 years with AMH below the 
10th percentile, have a compromised ovarian reserve. In some women, serial AMH 
measurements might follow the 10th percentile, since they have been on that level ever 
since, whereas other women might progress into menopause much faster and hence, 
their longitudinally assessed AMH concentrations will intersect different percentiles 
in a similar time span. However, serial measurements of ovarian reserve and follow-up 
of reproductive events might as well reveal that in some women AMH levels are low, 
without any consequences for their reproductive outcome.  
Consistent with recent studies (99, 102), a variable correlation between AMH and 
age was observed in our normative data (chapter 2.1). A previous study in rodents may 
provide a possible explanation for these findings (79). It was shown that during early 
reproductive life, AMH concentrations remained constant in mice, whereas the number 
of primordial follicles decreased steadily. Initially, the number of growing follicles was 
constant, suggesting that the rate of primordial follicle recruitment was increased 
during early reproductive life. Once the size of the primordial follicle pool fell below 
a certain threshold, the number of growing follicles did decline and concomitantly, 
serum AMH levels declined (79). In women, there is limited information on regulation 
of recruitment of primordial follicles. However, it may be possible that it follows a 
similar course as in mice. Hence, during adolescence and early reproductive life, the 
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growing follicle cohort is constant and AMH concentrations are constant, whereas the 
number of primordial follicles decrease steadily. From the age of 25 years onwards, 
the number of remaining primordial follicles has reached a certain threshold and as a 
consequence the size of the growing follicle cohort and AMH levels decline. Because 
of differences in the rate of primordial follicle recruitment and differences in the size 
of the primordial follicle pool, the onset of declining AMH levels may vary, reflecting 
the large variation in AMH concentrations and thus, variation in reproductive ageing. 
In other words, prior to the age of  25, the variation in AMH levels may reflect several 
different stages of reproductive ageing, i.e. a stage at which the number of growing 
follicles remains constant or a stage at which the cohort of growing follicles is declining. 
A specific group of women in whom assessment of the ovarian reserve is relevant 
are survivors of cancer (chapter 3.1 and 3.2). Gonadotoxicity is a known side-effect of 
cancer treatment and may damage primordial follicles as well as growing follicles (249, 
250). Depending on the extent of ovarian damage, accelerated follicle loss might result 
in a transient reduction in the size of the growing follicle cohort and consequently, a 
temporary ovarian dysfunction, whereas loss of primordial follicles might result in 
premature ovarian insufficiency (POI) (119, 136, 143, 154, 251-253). Hence,  female 
cancer survivors  are suspected of diminished ovarian reserve and its early detection 
is especially important in those who still might want to conceive. In chapter 3.1, it 
was shown that in premenopausal women who had received chemotherapy and 
total body irradiation for hematological cancer at adult age, serum AMH levels after 
treatment were undetectable and all women had developed acute POI. In addition, in 
premenopausal women treated with chemotherapy, serum AMH levels were lower than 
AMH levels in age-matched controls, despite restoration of menstrual cyclicity after 
cancer therapy. These results indicate that in female cancer survivors, AMH constitutes 
a useful marker of ovarian reserve. Moreover, assessment of AMH may be valuable to 
detect early decrease of ovarian reserve in women at risk to lose their reproductive 
capacity early in life. In young adult survivors of childhood cancer that had been treated 
with procarbazine-containing chemotherapy, in those who received irradiation to the 
abdomen and in survivors treated with total body irradiation, serum AMH levels were 
significantly lower than in age-matched healthy controls, indicating that these females 
may be at risk of POI. Indeed, in 27% (49/182) of our survivors, AMH levels were 
lower than the 10th percentile of normal values, suggesting that follicle loss in cancer 
survivors was accelerated as compared to that in controls (chapter 3.2). However, these 
results should be interpreted with caution, since they were based on a single assessment 
of ovarian reserve. Since a single AMH measurement only reflects the current status 
of the ovarian reserve and not the progression of follicle loss. Therefore, longitudinally 
designed studies with repeated assessments of AMH levels are recommended, which 
may provide more insight in the rate of follicle loss after cancer treatment. Moreover, 
the progression of follicle loss in cancer survivors should be compared with that in 
age-matched healthy control women over a similar period of follow-up, to determine 
whether in cancer survivors AMH levels within the normal range are predictive of 
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normal age at menopause or whether gonadotoxicity has accelerated primordial 
follicles loss,  resulting in POI. In addition, it would be useful to be able to predict the 
extent of ovarian damage and consequence of gonadotoxicity in each individual patient 
prior to therapy. A recent long term follow-up study showed that pretreatment AMH 
levels were predictive of restoration of menstrual cycles in women after treatment 
for breast cancer, independent of age at start of treatment (254). Although data on 
reproductive potential in survivors with restoration of menstrual cycles was lacking 
in that study and follow-up of AMH levels was not performed in a control cohort, 
these data do indicate that pretreatment assessment of the ovarian reserve may provide 
information on residual ovarian function after therapy. Consequently, cancer patients 
with low AMH levels at diagnosis seem to be at increased risk of POI after treatment. 
These females should be counseled on the possibilities of fertility preservation prior to 
initiation of cancer treatment. 
5.2. amH as marKer of normoGonadotropiC 
anoVulatorY dYsfunCtion and polYCYstiC 
oVaries
Because of the strong correlation between AMH and the number of small antral 
follicles, AMH has been described as a marker of ovarian dysfunction i.e. anovulatory 
infertility (146). Most women presenting with anovulatory infertility are diagnosed 
with normogonadotropic anovulatory dysfunction, class II according to the World 
Health Organization classification for anovulatory dysfunction (class WHO II). 
Among normogonadotropic anovulatory women, the polycystic ovary syndrome 
(PCOS) is a common endocrine disorder. PCOS is based on its clinical presentation, 
which encompasses a broad spectrum of symptoms (255). Typically, women with 
normogonadotropic  anovulation and PCOS present with high AMH levels as compared 
with normo-ovulatory women (51, 85), which seems to be attributable to an increased 
number of pre-antral and antral follicles (48).  Therefore, in chapter 4.1 we have tested 
the diagnostic value of AMH levels the presence of an excessive number of follicles, 
i.e. polycystic ovaries (PCO). Surprisingly, the largest proportion of women with PCO 
studied had AMH levels within the normal range. This finding may be explained by 
the wide the range in AMH levels and concomitant number of follicles in the regularly 
cycling, age-matched control women. More specifically, in normo-ovulatory control 
women between 18 and 30 years old, the median AFC was 18, and thus would be 
diagnosed as having PCO. Hence, the presence of 12 or more follicles per ovary in 
regularly cycling women is far more common than previously described (208, 216). 
In agreement, a recent study has suggested that the cut off level of 12 or more follicles 
may no longer be valid for the diagnosis of PCO.  Because of more accurate detection 
of small follicles, the threshold for PCO should be elevated to 19 follicles or more. In 
addition, the authors propose that the presence of 19 or more follicles per ovary in 
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women with regular menstrual cycles, thus, comparable to women described in our 
control cohort, may be a silent precursor form of PCOS (191). Indeed, several studies 
have described endocrine abnormalities, such as increased androgen and insulin levels 
in non-hirsute, normo-ovulatory women with PCO (103, 203, 256), indicating that 
PCOS  may be more common and far more heterogeneous than recognized until so far. 
Other studies have proposed that PCO is an age-dependent, common finding among 
ovulatory women (209, 210, 257). The presence of PCO in almost two-third of our 
control subjects supports the latter studies and suggests that the threshold of 12 or 
more follicles as cut-off level for PCO is not very specific for the diagnosis of PCOS 
(216). Consequently, the cut-off level for PCO may need to be revisited (191). Because 
of the age-related decline of the AFC, we propose that this cut-off level should be age-
dependent. Possibly, an age-adjusted and higher threshold for PCO may yield a more 
accurate diagnosis of PCO and thus, of PCOS in adolescents, with an increased follicle 
number (42). Longitudinal follow-up studies of menstrual cycles, follicle counts, 
endocrine and metabolic profiles in a random cohort of adolescents may provide more 
insights on the clinical significance of PCO in the diagnosis of PCOS.  
5.3. amH as a marKer of ooCYte qualitY 
Concomitant with the gradual decline of follicle numbers, an increased miscarriage rate 
and a higher incidence of children with chromosomal abnormalities have been observed 
at advanced maternal age, and are believed to be due to a decrease in oocyte quality 
(258, 259). Hence, the process of ovarian ageing is not only accompanied by a steady 
decrease in the number of ovarian follicles but is also associated with a concomitant 
decrease in oocyte quality (16). Studies on the two aspects of ovarian ageing in infertile 
women showed increased miscarriage rates and low chances of ongoing pregnancy in 
women with poor response to ART treatment cycles (260-262). Since poor response 
seems to reflect a decrease in the number of follicles (59), these findings suggest a 
possible relation between oocyte quantity and quality. However, other studies showed 
that markers predictive of poor response such as AFC,  serum FSH and inhibin B 
were not predictive of chances of ongoing pregnancy (16, 57, 101, 238, 263, 264). In 
agreement, in chapter 4.3, we describe that serum AMH levels were predictive of the 
number of oocytes retrieved after ovarian stimulation in infertile women aged up to 37 
years. However, there was no consistent correlation between AMH and embryo quality, 
expressed by aneuploidy rate and embryo morphology score or with fertilization rate. 
These results suggest that oocyte quantity and numerical chromosomal abnormalities 
are not tightly linked. Indeed, aneuploidic embryos have been observed after in vitro 
fertilization cycles in infertile women younger than 38 years, in whom FSH and inhibin 
B levels were within normal ranges (265). In addition, our data confirm that markers of 
the quantitative aspect of ovarian reserve, such as FSH, AFC and AMH, do predict the 
number of oocytes retrieved after ovarian stimulation, but do not constitute markers of 
oocyte quality. This suggests that, besides chromosomal segregation defects, multiple 
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factors may contribute to the developmental capacity of an oocyte, and that an accurate 
marker has yet to be identified.  Although the number of good quality oocytes is 
decreasing with increasing age, apparently a few normal oocytes are still present which 
can be recruited from time to time and especially during ART cycles.
In conclusion, the most important clinical application of serum AMH levels is 
assessment of ovarian reserve. Additional longitudinal follow-up studies are needed 
to determine a cut-off level at the lower limit of the normal range of serum AMH 
concentrations, that can be used to discriminate women at risk of infertility or early 
menopause (Table 5.1). Such studies may provide information on the rate of follicle loss 
and are required not only in healthy, normo-ovulatory women, but also in women at 
risk of POI, i.e. after gonadotoxic treatment. In addition, serum AMH concentrations 
at diagnosis may predict residual ovarian reserve after cancer treatment. Longitudinal 
follow-up studies of ovarian reserve in cancer survivors may provide insight into 
the progression of follicle loss after gonadotoxic treatment and the consequences for 
reproductive potential (Table 5.1). In the diagnosis of PCOS, the role of AMH seems 
to be limited; most studied PCOS women had AMH levels within the normal range 
and consequently, the upper limit of the normal range of AMH levels in normo-
ovulatory women needs further investigation (Table 5.1). Concomitantly, normo-
ovulatory adolescents and young adults women should be screened on the presence 
of PCO, since our data indicate that this may be a rather physiological phenomenon. 
Furthermore, these adolescents and women might have an occult form of PCOS, and 
therefore, screening of endocrine profiles, especially serum androgen levels, should 
also be included. Confirmation of the current findings may require the assessment of a 
new threshold for the presence of PCO and thus, for the diagnosis of PCOS.
Population Research topic
General population Prediction of decreased fertility and age of menopause  
Variation in the age of menopause
Follicular dynamics during childhood and adolescence
Prevalence of polycystic ovaries and polycystic ovary syndrome
Cancer survivors Prediction of residual ovarian function after cancer treatment 
Follicular dynamics after cancer treatment
Table 5.1. Recommendations for future research
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summarY 
The ovary is of major importance  in the process of reproduction and hormone 
production. The age-related decrease in ovarian follicles and a concomitant decline 
in oocyte quality dictate the occurrence of natural loss of fertility and, ultimately, 
menopause. Over the past few decades, postponement of childbearing has led to a shift 
of the age at which women deliver their first child towards the age at which fertility 
starts to decrease. Consequently, the incidence of age-related female subfertility has 
increased and as a consequence the need for assisted reproductive treatment. Since 
ovarian reserve is predictive of ovarian response during assisted reproductive treatment, 
increased attention has been given to the identification of markers of ovarian reserve. 
Chapter 1, the general introduction, provides the background of ovarian physiology, 
ovarian reserve and ovarian pathophysiology. In addition, the most currently used 
markers of ovarian reserve are described. Pre-clinical and clinical studies, discussed 
in detail in this first chapter, confirmed that serum AMH concentrations constitute 
a marker of ovarian reserve and ovarian pathophysiology, such as polycystic ovary 
syndrome (PCOS). The aim of the thesis was to study clinical applications of serum 
AMH as marker of ovarian reserve and ovarian dysfunction. 
Chapter 2 describes normal values of AMH in a large cohort of healthy females, 
ranging from childhood to the end of the reproductive lifespan. During childhood, 
serum AMH increased with advancing age, whereas in adults from the age of 25 years 
onwards, serum AMH levels and age were inversely correlated. This suggests that 
follicular dynamics during childhood might differ from that at adult age and implies 
that AMH is only applicable as marker of ovarian reserve in women of 25 years and 
older. In addition, the inter-individual range in serum AMH levels was very large at 
any given age. Most likely, this reflects the large  variation in age of menopause.  
The second part of the thesis addresses ovarian reserve in cancer survivors. 
Gonadotoxicity is a well-known side effect of cancer therapy, which may lead 
to premature ovarian insufficiency (POI). However, the extent of the damage is 
unpredictable.  Chapter 3.1 describes the predictive value of serum AMH levels for the 
residual ovarian reserve in women with haematological malignancies. In all patients, 
AMH concentrations were lower than in age-matched controls prior to treatment, 
suggesting that in cancer patients the ovarian reserve might already be compromised 
prior to any therapy. Patients who had received total body irradiation all developed POI 
and in this subgroup of cancer patients fertility preservation should be considered. In 
the studied cohort of cancer survivors, serum AMH levels prior to therapy were not 
predictive of the residual ovarian reserve after cancer therapy. 
Ovarian reserve in survivors of childhood cancer was investigated in chapter 
3.2. Serum AMH concentrations in the total cohort were not different from controls. 
However, significantly lower AMH levels were observed in survivors treated with 
procarbazine-containing chemotherapy cycles, with abdominal or total body 
irradiation. Consequently, also in adults who had been treated for cancer during 
childhood or adolescence, serum AMH can be used to identify subgroups at risk for 
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decreased fertility or POI. Some of these childhood cancer survivors had become 
pregnant. Pregnancy outcome in a cohort of childhood cancer survivors was described 
in chapter 3.3. Pregnancy outcome was not different between survivors and controls 
in the total cohort. However, survivors treated with abdominal radiotherapy delivered 
preterm and had post-partum hemorrhage. Therefore, we recommend that this group 
of childhood cancer survivors needs inpatient perinatal care and close monitoring of 
the delivery. 
In chapter 4 the role of serum AMH as marker a of ovarian pathophysiology was 
investigated. First, in chapter 4.1, the diagnostic value of AMH in the classification of 
anovulatory dysfunction and in the prediction of polycystic ovaries was assessed in a 
large cohort of anovulatory women. Based on AMH levels, hypogonadotropic women 
could not be discriminated from normogonadotropic women and the value of serum 
AMH levels as a diagnostic marker of anovulatory dysfunction seemed to be limited to 
the prediction of hypergonadotropic anovulation. Serum AMH levels were predictive 
of PCO and might therefore replace PCO as a criterion in the diagnosis of PCOS. 
However, especially in young control subjects also PCO was observed. This finding 
suggests that the threshold for PCO is age-dependent and stresses the need to revise 
the Rotterdam consensus criteria for PCOS.  
AMH is considered as accurate predictor of ovarian response in controlled ovarian 
stimulation for in vitro fertilization treatment cycles. It was hypothesized in chapter 
4.2 that serum AMH concentrations might also be a marker of ovarian response 
during ovulation induction treatment with low dose exogenous gonadotrophins in 
women with PCOS, since these women are at risk of multiple follicular growth. Serum 
AMH concentrations remained stable during ovulation induction in PCOS women, 
which was similar to the findings in natural cycles. Apparently, follicular dynamics 
in ovulation induction treatment cycles with low dose exogenous gonadotrophins are 
different from those during controlled ovarian hyperstimulation. Therefore, in these 
PCOS women, serum AMH concentrations did not seem to be useful as marker of 
ovarian response in low dose ovarian stimulation cycles. 
Ovarian ageing encompasses not only decrease in the number of oocytes, but also 
oocyte quality decreases with increasing age. In chapter 4.3 the predictive value of 
AMH as marker of oocyte quantity and embryo quality was studied in women with 
regular menstrual cycles and younger than 37 years. Serum AMH concentrations 
determined on cycle day three were predictive for ovarian response to stimulation. 
However, the lack of a consistent correlation between AMH and embryo morphology 
and embryo aneuploidy rate suggests that oocyte quantity and embryo quality are not 
directly related. 
In chapter 5, the general discussion, the different applications of serum AMH 
concentrations are considered. Based on the current studies, the most important role 
for AMH in clinical practice is assessment of ovarian reserve, in healthy women as well 
as in women treated with gonadotoxic agents in the past. In addition, suggestions are 
made for future research to further establish the role of AMH as marker of ovarian 
reserve and ovarian dysfunction. 
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samenVattinG
De eierstok (het ovarium) is een belangrijk orgaan voor de voortplanting en 
hormonenproductie. Met toenemende leeftijd neemt het aantal en de kwaliteit van de 
eiblaasjes (follikels) in het ovarium,  ofwel de ovariële reserve, geleidelijk af en neemt ook 
de vruchtbaarheid af. Uiteindelijk zijn er zo weinig follikels over, dat de menstruaties 
stoppen en de menopauze is bereikt. Door de groeiende welvaart van de afgelopen 
decennia, hebben vrouwen hun kinderwens steeds verder uitgesteld, zodat de leeftijd 
waarop vrouwen hun eerste kind krijgen steeds verder opschuift richting de leeftijd 
waarop de vruchtbaarheid begint te verminderen. Als gevolg hiervan is er, om zwanger 
te kunnen worden, een toenemende vraag naar vruchtbaarheidsbehandelingen, ofwel 
geassisteerde voortplanting. De uitkomst van deze behandelingen wordt sterk bepaald 
door het aantal follikels in de eierstokken. Daarom is het van belang om dit aantal 
zo nauwkeurig mogelijk te kunnen inschatten. In hoofdstuk 1 wordt een overzicht 
gegeven van de normale follikelgroei en ontwikkeling, de ovariële reserve en verstoorde 
follikelgroei. Daarnaast worden verschillende markers van ovariële reserve besproken. 
Recent is het anti-Müllers hormoon (AMH) beschreven als nieuwe en accurate marker 
van de ovariële reserve. Klinische studies worden beschreven, die aantonen dat AMH 
waarden in serum een goede weergave zijn van het aantal groeiende follikels. Derhalve 
kan AMH als marker van de ovariële reserve worden gebruikt en als marker voor 
disfunctioneren van de eierstok, zoals in het  polycysteus ovarium syndroom (PCOS), 
waarbij er een overschot aan antrale follikels is. In dit proefschrift wordt beschreven 
in hoeverre AMH kan worden toegepast als marker van ovariële reserve en ovarieel 
disfunctioneren.
In hoofdstuk 2 worden normaalwaarden van AMH beschreven in een groot cohort 
vrouwen, van kinderleeftijd tot het eind van de vruchtbare levensfase. Op kinderleeftijd 
was er een lichte stijging in AMH waarden. Vanaf de leeftijd van 25 jaar, daalden AMH 
waarden met toenemende leeftijd. Dit lijkt te duiden op een verschil in follikeldynamiek 
op kinderleeftijd ten opzichte van volwassenleeftijd en dat AMH pas als marker voor 
ovariële reserve te gebruiken is vanaf de leeftijd van 25 jaar. Daarnaast was er op elke 
leeftijd een grote inter-individuele range in AMH waarden. Zeer waarschijnlijk is dit 
een weergave van de aanzienlijke variatie in menopauzeleeftijd.  
Hoofdstuk 3 is gewijd aan ovariële functie en reserve in overlevenden van kanker. 
Gonadotoxiciteit is een bekende bijwerking van verschillende kankerbehandelingen, 
die schade aan de eierstokken veroorzaakt, waardoor versnelde afbraak van primordiale 
follikels kan optreden. Vrouwen die een gonadotoxische behandeling hebben ondergaan 
lopen daarom het risico op jonge leeftijd al verminderd vruchtbaar te zijn en vervroegd 
in de overgang te komen. De mate van ovariële schade na behandeling is echter niet te 
voorspellen. In hoofdstuk 3.1 wordt onderzocht of AMH vóór behandeling van kanker 
voorspellend is voor de ovariële reserve na de behandeling. AMH werd gemeten voor en 
na therapie in vrouwen die werden behandeld voor hematologische nieuwvormingen 
en werd vergeleken met AMH in vrouwen van vergelijkbare leeftijd, met normale 
ovariële functie, de controle groep. In alle patiënten was AMH voor de behandeling 
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lager dan in de controles, wat erop kan wijzen dat de ovariële reserve vóór enige 
kankerbehandeling al gecompromitteerd kan zijn. Vrouwen die werden behandeld met 
bestraling over het gehele lichaam waren na deze behandeling allen vervroegd in de 
overgang. Deze vrouwen moeten daarom worden gecounseld voor de mogelijkheid tot 
fertiliteitspreservatie. In dit cohort vrouwen, was AMH vóór kankerbehandeling niet 
voorspellend voor de ovariële reserve na behandeling. 
Hoofdstuk 3.2 beschrijft serum AMH concentraties van vrouwen die op 
kinderleeftijd zijn behandeld voor kanker. In de gehele groep vrouwen was AMH 
niet verschillend van de controle vrouwen. Echter, vrouwen die waren behandeld 
met minimaal 3 chemotherapiebehandelingen met procarbazine hadden lagere AMH 
waarden dan controles, evenals vrouwen die bestraling op het gehele lichaam of op de 
buik hadden gehad. Ook in volwassen vrouwen die op kinderleeftijd zijn behandeld voor 
kanker, kan op basis van AMH een verhoogd risico op verminderde vruchtbaarheid of 
vervroegde menopauze worden opgespoord. Zwangerschapsuitkomsten in een deel van 
de vrouwen die behandeld werden voor kinder- en jeugdkanker werden vergeleken met 
data uit een groot nationaal cohort en beschreven in hoofdstuk 3.3. Over het algemeen 
waren er geen verschillen in zwangerschapsuitkomst tussen de vrouwen die kanker 
hadden gehad en controles. Echter, vrouwen die waren behandeld met buikbestraling 
bevielen bij een vroegere zwangerschapsduur en hadden vaker een fluxus postpartum 
(bloedverlies >1 liter). Daarom adviseren wij dat vrouwen die behandeld zijn voor 
kanker een medische indicatie krijgen voor de zwangerschap en de partus. 
In hoofdstuk 4 wordt de rol van AMH als marker van ovariële disfunctie onderzocht. 
Hoofdstuk 4.1 beschrijft de voorspellende waarde van AMH bij het diagnosticeren 
van de drie belangrijkste oorzaken van het uitblijven van de eisprong (anovulatie) 
en bij de diagnose van PCOS. Op basis van alleen een AMH waarde, was het niet 
mogelijk om vrouwen met hypogonadotrope anovulatie te onderscheiden van vrouwen 
met normogonadotrope anovulatie, omdat beide groepen normale AMH waarden 
hadden. AMH in serum heeft met name een voorspellende waarde bij de diagnose 
van hypergonadotrope anovulatie, het voortijdig verouderen van de eierstokken. 
Hoge AMH waarden waren zeer specifiek was voor de aanwezigheid van polycysteuze 
ovaria (PCO). Omdat een groot deel van de jonge gezonde controle vrouwen ook 
PCO hadden, lijkt het dat de afkapwaarde voor de diagnose van PCO moet worden 
aangepast op basis van de leeftijd, hetgeen gevolgen heeft voor de diagnose van PCOS. 
In hoofdstuk 4.2 wordt verondersteld dat tijdens ovulatie inductie behandeling 
in vrouwen met PCOS eenzelfde daling in AMH kan worden waargenomen zoals 
tijdens een in vitro fertilisatie (IVF) behandeling. De aanmaak van AMH neemt af 
naarmate follikels groter worden en tijdens stimulatie voor een IVF behandeling zal 
de serum AMH concentratie afnemen. Bij ovulatie inductie behandelingen wordt de 
eisprong van een eiblaasje op gang gebracht. AMH waarden bleven stabiel tijdens de 
ovulatie-inductie behandeling in bijna alle PCOS vrouwen en er was geen verschil met 
de verandering van AMH tijdens een normale menstruele cyclus. Blijkbaar lijkt de 
follikeldynamiek tijdens een ovulatie inductie cyclus meer op die van een normale 
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menstruatie cyclus, dan de follikeldynamiek tijdens ovariële stimulatie voor IVF. 
Serum AMH waarden lijken daarom niet bruikbaar als marker van respons tijdens 
ovulatie inductie behandeling in PCOS vrouwen. 
Naarmate de eierstokken verouderen is er niet alleen sprake van afname van het 
aantal follikels, maar er is ook een verminderde kwaliteit van de oocyten. In hoofdstuk 
4.3 wordt onderzocht of serum AMH waarden voorspellend zijn voor zowel het aantal 
follikels als de kwaliteit van embryo’s na ovariële stimulatie bij IVF behandeling. 
Vrouwen jonger dan 37 jaar met regelmatige menstruaties werden gerandomiseerd 
voor ovariële stimulatie volgens het standaard IVF protocol dan wel volgens een 
mild stimulatie schema. Serum AMH correleerde met het aantal verkregen eicellen 
(oocyten). AMH was gecorreleerd met embryo morfologie, in embryo’s verkregen 
na milde stimulatie, maar niet na standaard stimulatie.  Concluderend is AMH 
voorspellend voor het aantal verkregen oocyten. De inconsistente correlatie tussen 
AMH en embryo morfologie pleit tegen het bestaan van een directe relatie tussen oocyt 
kwantiteit en embryo kwaliteit. 
Hoofdstuk 5, het laatste hoofdstuk, is een algemene beschouwing van de relevantie 
van de klinische toepassingen van AMH. Ook de noodzaak aan en mogelijkheden voor 
toekomstig onderzoek naar de rol van AMH worden besproken. 
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danKWoord
Tijdens de verschillende fasen van mijn onderzoek, het schrijven en afronden van dit 
proefschrift heb ik veel mensen leren kennen. Graag wil ik in dit laatste deel iedereen 
die op enige manier een bijdrage heeft geleverd aan dit resultaat enorm bedanken voor 
zijn of haar hulp, steun en interesse. In het bijzonder wil ik nog een aantal mensen 
bedanken. 
Professor Laven, beste Joop. ‘Promotie traject beginnend op 1 juni 2005 t/m 1 juni 2008 
(eventuele uitloop met één jaar mogelijk)’, schreef je in onze eerste correspondentie 
voor de start van mijn promotietraject. Uiteindelijk, zeven jaar later, is het boekje dan 
toch af. Veel dank voor je geduld en vertrouwen. Als promotor had je graag de touwtjes 
in eigen handen, maar het stellen van deadlines liet je over aan de promovendus zelf. 
Sinds je benoeming werd je aandacht iets meer verdeeld, maar de deur stond altijd 
open voor je promovendi en elk artikel werd steeds met kritische blik beoordeeld. Ook 
wil ik je bedanken voor je interesse en bezorgdheid om mijn schildklierfunctie en je 
bijdrage aan onze ‘mooie mannen kast’.
Professor Themmen, beste Axel. Vanaf het begin was jij nauw betrokken bij de opzet 
van mijn proefschrift. Naarmate het meer vorm kreeg, liet je de directe begeleiding 
meer over aan de andere leden van het team. Graag wil ik je bedanken dat jij me hebt 
geleerd hoe ik de format moet maken voor een figuur als bijlage bij een artikel. Ik heb 
er veel profijt van gehad. 
Dr. Schipper, beste Jits. Je werd aan mij voorgesteld als ‘de co-promotor: iemand waar 
je je aan vastklampt ‘. In de loop der tijd bleek dat jij op een terras met een goed glas 
bier het gemakkelijkst inspiratie op doet voor het schrijven van de discussie. Helaas 
is dit er door je drukke klinische en onderwijsactiviteiten nooit echt van gekomen. 
Wel kon ik altijd even langskomen voor een brainstormsessie, statistisch advies of het 
bespreken van resultaten. Ik had me geen andere co-promotor kunnen bedenken die 
zo ontspannen is. Dank voor je fijne begeleiding. 
Dr. ir. Visser, beste Jenny. Je raakte pas in de loop van mijn promotietraject meer 
betrokken bij mijn onderzoek. Hoewel mijn onderzoek heel klinisch is, heb je met 
je biologische achtergrond steeds weer de basale kant ervan benadrukt. Ik vind het 
knap hoe snel je je mail kan beantwoorden – zelfs op vakantie en je verschillende 
werkzaamheden combineert. Daarnaast weet je dat promoveren ook buiten reguliere 
werktijden gebeurt, vooral op congressen, feestjes en borrels. Dank voor je fijne 
begeleiding. 
Dr. van den Heuvel, beste Marry. Ook onze samenwerking begon pas later in mijn 
promotietraject. Het was verfrissend om eens door de bril van een kinderoncoloog 
naar fertiliteit te kijken. Ik bewonder de manier waarop je de QCAT werkgroep hebt 
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vormgegeven en aanstuurt, naast je drukke klinische werkzaamheden. Dank voor je 
enthousiasme en steun in voorbereiding op en tijdens mijn eerste presentatie op een 
internationaal congres en het heel snel regelen van een CT-scan toen het nodig was. 
Professor de Jong, beste Frank. Dank voor je bijdrage aan bijna alle hoofdstukken van dit 
proefschrift, het meermaals beantwoorden van de vraag ‘hoe het nu precies zit met de 
verschillende assays’ en ook veel dank voor de leerzame endocrinologiebesprekingen. 
Professor Fauser, bedankt voor uw input als mede-auteur van verschillende artikelen 
en het kritisch lezen van het manuscript. 
Professor Sonneveld, bedankt voor het kritisch lezen van het proefschrift. 
Dr. Lugtenburg, beste Elly. Dank voor je enthousiaste begeleiding van mijn eerste 
onderzoek. 
Professor van der Lely, beste Aart-Jan. Dank voor het kritisch doornemen van het 
manuscript en voor het willen plaatsnemen in de commissie.
Professor Hokken, dank voor het beschikbaar stellen van samples uit uw eerdere 
studies en uw kritische bijdrage als mede-auteur.
De verschillende mede-auteurs die hebben bijgedragen aan de artikelen van dit 
proefschrift wil ik graag bedanken: Esther Baart, Elena Martini, Friederike Hakvoort, 
Frank Broekmans, Corinne Welt, Chantal Hukkelhoven, Eric Steegers. 
De collega’s van de subafdeling Voortplantingsgeneeskunde, en dan in het bijzonder 
de fertiliteitsartsen wil ik danken voor het feit dat zij er op tijd aan dachten bloed 
af te nemen bij patiënten tijdens ovulatie-inductie cycli: Berthe, Elizabeth, Hjelmar, 
Paulien, Nicole en Jenny. Ook veel dank aan Lizka, Jolanda, Wouter en alle analisten 
van het IVF-lab voor hun interesse in mijn project en hun logistieke hulp, waar dit ook 
mogelijk was. 
Veel dank ben ik verschuldigd aan Brigitta van de Lang voor het meten van de vele 
AMH samples, het invoeren en omrekenen van de vele resultaten. Ook dank aan 
Yolanda de Rijke voor het faciliteren hiervan.   
René Eijkemans, veel dank voor je uitleg van biostatistische problemen op een niveau 
begrijpbaar voor een clinicus en voor je geduld tijdens de analyses bij de PRN.
Mijn (ex)-collega-(arts)-onderzoekers verspreid over het Erasmus MC: Olivier, Lindy, 
Emily, Fatima, Durk, Annelindy, Mariëlle, Jolanda, Annelous, Anneke, Dineke, Lydi, 
Christine, Robbert, Melek, Sarah, John, Babs, Jashvant, Evelyne, Annelien en Nicolette. 
Bedankt voor de gezelligheid tijdens de lunches, borrels en verjaardagstaarten. 
Speciale dank aan de kamergenootjes op thuisbasis Hs-508. Bedankt voor jullie 
gezelligheid, luisterend oor en relativeringsvermogen. Olivier, ik bewonder de manier 
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waarop je in het leven staat, hoe jij je onderzoek, opleiding en vaderschap combineert. 
Veel sterkte met voor jou nu toch ook de laatste loodjes en hopelijk kunnen we nog 
eens gezellig op congres naar Disney World. Yvon, wat gezellig dat jij het team van 
arts-onderzoekers van de VPL kwam versterken. Ik vind het heel knap hoe jij je in 
korte tijd meester maakte van de genetica van de gynaecologie. En gelukkig hoef je 
maar tot oktober, toch? Lin, ook ik zal onze eerste ontmoeting niet snel vergeten. Ik 
vond het supergezellig om naast je te zitten. Jammer dat het nu wat langer duurt voor 
we samen in het Erasmus zitten. Annelindy, inmiddels woon en werk je wat verder weg 
dan aanvankelijk het plan was. Veel succes met je opleiding en ook jij bedankt voor 
de koelkast. Mariëlle, ook jij bent in opleiding tot iets anders dan gynaecoloog. Veel 
succes op 2 mei - helaas kan ik er niet bij zijn, maar je gaat het heel goed doen. Ook 
speciale dank aan Sam, klein beetje buitenbeentje bij de VPL, maar volop aanwezig 
op VPL congressen met verlenging. Ik kijk ernaar uit om met je samen te werken in 
het Erasmus. Paul, dank voor je gezelligheid tijdens de vele discipline-overstijgende-
onderzoeksmomenten al dan niet tijdens de reguliere werktijden. Veel succes met het 
afronden van jouw promotietraject. 
Collega’s uit het Maasstad Ziekenhuis: gynaecologen, A(N)IOS, verpleegkundigen, 
poli-medewerksters, secretaresses. Beginnen met de opleiding als ex-onderzoeker in 
jullie kliniek deed me snel beseffen waar ik dit nu allemaal voor heb gedaan. Bedankt 
voor de gezellige en leerzame jaren, ik kon me geen betere start van mijn opleiding 
bedenken dan in jullie team. Tot binnenkort. 
Lieve vrienden en vriendinnen. Marjolein, Andrew, Gré, Oliver, Mirjam, Es, Andy, 
Koen, Leen, Wim, Maarten, Olivier, Charlot, Remco, Annemiek, Frank, Sandra, 
Harald, Siebe dank voor jullie begrip tijdens mijn stralende afwezigheid op meerdere 
verjaardagsfeestjes, babyshowers, kraambezoeken en etentjes. Ik kom snel alles inhalen. 
Lieve Peggy, het was voor mij al vrij snel duidelijk dat jij mijn paranimf zou worden. 
Ik herinner me nog heel goed onze eerste date in WP in 2003! Wat is er sindsdien veel 
gebeurd. In 2005 jij in opleiding, ik gestart als arts-onderzoeker; onze vriendschap werd 
alleen maar hechter. Dank dat je op 27 april naast mij wil staan en laten we proosten op 
nog veel meer, nog mooiere vriendschapsjaren. 
Lieve Wen, hoewel onze eerste date veel minder lang geleden is vind ik het erg fijn dat 
ook jij mijn paranimf wilt zijn. Dank dat je met zoveel toewijding en enthousiasme 
(een deel van) mijn onderzoek verder zet. Nog eindeloos meer dank voor het nazoeken 
en omrekenen van de vele AMH waarden! Zonder jou had het hele traject nog langer 
geduurd. Veel succes met je eigen onderzoek en ….. ASRM Hawaï, here we come! 
Lieve Isabellita en Klaas-Jan. Dank voor jullie interesse in ‘het levenswerk’ en nog meer 
dank voor jullie attente support en welkome afleiding tijdens de soms zware avonden 
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en weekends. Laten we de spontane zondagavondetentjes, inclusief voetbal, nog lang 
voortzetten. 
Lieve ma en pa. Het bleef soms toch wat onduidelijk voor jullie wat ik nu de hele dag 
zo deed aan de computer, maar de klus is nu geklaard. Bedankt dat jullie me altijd 
hebben gesteund in mijn keuzes, me hebben gestimuleerd om mezelf te ontwikkelen 
en nieuwsgierig te blijven. Dit proefschrift is af, mede door jullie. 
Lieve Bart. Bedankt dat je er altijd voor me bent. 
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